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1. ABSTRACT
    The  objective  of  this  research  work  was  to  formulate,  develop  and  evaluate
combination  of  immediate  release  (IR)  tablets  of  Tenofovir  DF  and  Lamivudine.
Tenofovir  DF and Lamivudine  are nucleotide and nucleoside reverse  transcriptase
inhibitor. These drugs have to be given in combination otherwise HIV virus develops
resistance  to  these  drugs.The  tablets  were  prepared  by  dry  granulation  and  wet
granulation method. For the Immediate release formulation the disintegration time of
the tablet must be optimised in order to have a faster release of drug in the dissolution
profile.  The  disintegration  time  is  managed  by  using  the  superdisintegrants  like
Croscarmellose  sodium,  sodium starch  glycolate  Type  A in  the  formulation.  The
formulation trials were optimised by incorporating varying composition of Lactose
monohydrate, microcrystalline cellulose as diluents, Croscarmellose sodium, Sodium
starch  glycolate  Type-A  as  Superdisintegrants,  Pregelatinized  starch  as  binder,
Magnesium stearate as lubricant. When the two drugs are combined the percentage
release  of  the  drugs  was  not  matching  with  the  innovator  samples.  So  it  was
formulated as  film coated  immediate  release  bilayered  tablets.  The preformulation
parameters such as bulk density, tapped density, compressibility index and hausner’s
ratio  were  analysed  for  prepared  granules  before  compression.  The  thickness,
hardness, friability, weight variation, disintegration time and drug content uniformity
was evaluated for  core and coated tablets.  The In-Vitro drug release studied were
performed in the USP Apparatus-II (Paddle) using 0.1N HCl as a dissolution media at
50rpm speed and temperature of 37°c ± 0.5°c. The % drug release at different time
interval was estimated using UV method. Based on the evaluation result F9 trial was
selected as the best formulation. These results indicated that the selected formulation
was stable during the test period of accelerated stability studies.  The In-vitro drug
release  profile  of  the  drugs  was  compared  with  marketed  reference  products  of
Tenofovir DF and Lamivudine. All the evaluated result was found to be satisfied with
the reference products.         
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Introduction
2. INTRODUCTION
2.1 ORAL DRUG DELIVERY1-5
Oral  drug delivery has  been known for  decades  as  the most widely utilized route of
administration among all the routes that have been explored for the systemic delivery of
drugs via various pharmaceutical products of different dosage forms. The reasons that the
oral route achieved such popularity may be in part due to its ease of administration as
well as the traditional belief that by oral administration the drug is well absorbed along
with the gastrointestinal tract along with food stuff. It is the most desirable and preferred
method of administering therapeutic agents for their systemic effects. In addition, the oral
medication is generally considered as the first avenue investigated in the discovery and
development of new drug entities and pharmaceutical formulations, mainly because of
patient  acceptance,  convenience  in  administration,  and  cost-effective  manufacturing
process. 
For  many  decades  various  pharmaceutical  dosage  form  such  as  tablets,  capsules,
suppositories, creams, ointments, liquids, aerosols, and injectables have been used for the
delivery  of  drugs  to  the  patients  for  the  treatment  of  various  diseases.  Even  today
conventional dosage forms are the primary pharmaceutical vehicles commonly seen in
the prescription and over the counter drug market. The oral conventional types of dosage
form are known to provide a prompt release of drug. The success of any technology relies
on the ease of its manufacturing process and its desirable biopharmaceutical properties.
The basic goal of drug therapy is to achieve a therapeutic effect. Almost 90% of all the
drugs  used  to  produce  systemic  effect  are  administered  by  oral  route.  Tableted  drug
delivery systems can range from relatively simple immediate release (IR) formulation to
complex  extended  or  modified  release  dosage  forms.  In  any  solid  dosage  forms,  an
important variable is the rate at which the active substance goes into solution or dissolves
to reach the systemic circulation. Dissolution of the active substance is essential for it to
be absorbed through the biological membranes into systemic circulation for eliciting its
desired pharmacological activity. The most important role of a drug delivery system is to
get the drug “delivered” to the site of action in sufficient amount and at the appropriate
rate.
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2.2 TABLETS7-8
Tablets may be defined as solid pharmaceutical dosage forms containing drug substances
with  or  without  suitable  diluents  and  prepared  either  by  compression  or  molding
methods. They have been in widespread use since the latter part of the 19th  century and
their popularity continues. 
Tablets remain popular as a dosage form because of the advantages, afforded both to the
manufacturer [e.g.:  simplicity & economy of preparation,  stability and convenience in
packing, shipping and dispensing] and the patient [e.g.: accuracy of dosage, compactness,
post ability, blandness of taste and ease of administration].
Although tablets are more frequently discoid in shape,  they also may be round, oval,
oblong, cylindrical or triangular. They may differ greatly in size and weight depending on
the amount of drug substance present and the intended method of administration.
2.2.1 Properties of Tablets:
The attributes of an acceptable tablet are as follows:
 The tablet must be sufficiently strong and resistance to shock and abrasion and to
withstand handling, during manufacturing, packing, shipping, and use. Hardness and
friability tests measure this property.
 Tablet must be uniform in weight and in drug content of the individual tablet. This is
measured by the weight variation and content uniformity tests.
 The  drug  content  of  the  tablet  must  show good  bioavailability.  This  property  is
measured by the dissolution test. Accurate bioavailability can be obtained from the
drug levels of the drug after its administration.
 Tablets must be elegant in appearance and must have characteristic shape, color, and
other markings necessary to identify the product.
 Tablets must retain all these functional attributes, which include drug stability and
efficacy. 
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2.2.2Advantages of Tablets:
 They are easy to administer.
 They are a unit dosage form, and they offer the greater capabilities of all oral dosage
forms for the greatest dose precision and the least content variability.
 Their cost is lowest of all oral dosage forms.
 They are the lightest and most compact of all oral dosage forms.
 Product identification is potentially the simplest and cheapest, requiring no additional
processing steps when employing an embossed or monogrammed punch face.
 They are in general the easiest and cheapest to package and ship of all oral dosage
forms.
 They may provide the greatest ease of swallowing with the least tendency for “hang-
up” above the stomach. Especially when coated, provided that tablet disintegration is
not excessively rapid.
 They lend themselves to certain special release profile products, such as enteric or
delayed release products.
 They are better suited to large-scale production than other unit oral forms.
 They have the best-combined properties of chemical, mechanical and microbiological
stability of all the oral forms. 
 One of the major advantages of tablet over capsules is that the tablet is essentially
“tamperproof dosage form”.
2.2.3Disadvantages of Tablets:
 Some drugs resist compression into dense compacts, owing to their amorphous nature
or flocculent, low-density character.
 Drugs with poor wetting slow dissolution properties, intermediate to large dosages,
optimum absorption high in the gastrointestinal  tract  or  any combination of these
features may be difficult or impossible to formulate and manufacture as a tablet that
will still provide adequate or full drug bioavailability.
 Bitter  tasting  drugs,  drugs  with  objectionable  odor  or  drugs  that  are  sensitive  to
oxygen or atmosphere moisture may require encapsulation or a special type of coating
with may increase the most of the finished tablets.  
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2.2.4 Types of Tablets:
Tablets are classified according to their route of administration or function.
 1. Tablets ingested orally 
a) Compressed tablets
b) Multiple compressed tablets
c) Multilayered tablets
d) Sustained action tablets
e) Enteric coated tablets
f) Sugar coated tablets
g) Film coated tablets
h) Chewable tablets
 2.  Tablets used in the oral cavity
a) Buccal tablets
b) Sublingual tablets
c) Lozenge tablets and troches  
d) Dental cones
              3.  Tablets administered by other routes
a) Implantation tablets
b) Vaginal tablets
               4.  Tablets used to prepare solutions 
a) Effervescent tablets
             5.  Molded tablets or tablet triturates (TT)
            a)   Dispensing tablets (DT)
b) Hypodermic tablets (HT)
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2.2.5 Tablet Manufacturing:
Tablets are compressed powders and their manufacturing is a complex, multistep process.
The ultimate aim is to easily disperse in gastrointestinal fluid and complete absorption of
API and at the same time, offer stability to the formulation.
The tablet manufacturing process can be broadly classified as:
1) Granulation method
a. Wet granulation method
b. Dry granulation method
2) Direct compression method
2.3 IMMEDIATE RELEASE TABLETS6
Pharmaceutical products designed for oral delivery and currently available on the
prescription and over-the-counter markets are mostly the immediate release type, which
are designed for immediate release of drug for rapid absorption.
Disintegrating agents are substances routinely included in tablet formulations and
in some hard shell capsule formulations in order to promote moisture penetration and
dispersion of the matrix of the dosage form in dissolution fluids. Superdisintegrants used
to improve disintegrant efficiency resulting in decreased use levels when compared to
traditional disintegrants.
Starch has been the disintegrant  of choice in  tablet  formulation,  and it  is  still
widely used. For instance, starch generally has to be present at levels greater than 5% to
adversely  affect  compatibility,  especially  in  case  of  direct  compression.  Drug  release
from a solid dosage form can be promoted by addition of suitable disintegrants. 
1.3.1 Definition: 
The term immediate release pharmaceutical formulation includes any formulation in which
the rate of release of drug from the formulation and the absorption of drug was neither
appreciably nor intentionally retarded by galenic manipulations. Immediate release may be
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provided along with an appropriate pharmaceutically acceptable diluent or carrier, in which
diluent or carrier does not prolong the rate of drug release and absorption.
The term “release” includes the presentation of the drug from the formulation in to the
GIT, to body tissues and into the systemic circulation. For GIT release, the release is under
pH conditions such as pH=1-3. The formulation of invention may release at least  70%
(preferably 80%) of active ingredient within 4 hours, such as within 3 hours, preferably 2
hours, more preferably within 1.5 hours, and especially within an hour (within 30 minutes)
of administration, whether it may be oral or parenteral.
2.3.2  DESIRED  CRITERIA  FOR  IMMEDIATE  RELEASE  DRUG  DELIVERY
SYSTEM:
Immediate release dosage form should- 
1. In the case of solid dosage form it should dissolve or disintegrate in the stomach within a
short period. 
2. In the case of liquid dosage form it should be compatible with taste masking. 
3. It should be portable without fragility concern. 
4. Should have a pleasing mouth feel. 
5. It shouldn’t leave minimal or no residue in the mouth after oral administration. 
6. Exhibit low sensitivity to environmental condition such as humidity and temperature.
7. It should be able to manufacture using conventional processing and packaging equipment
at low cost. 
8. Rapid dissolution and absorption of drug, which may produce quick onset of action. 
 2.3.3 ADVANTAGES OF IMMEDIATE RELEASE DRUG DELIVERY SYSTEM 
An immediate release pharmaceutical preparation offers: 
1. Improved compliance 
2. Improved stability 
3. Suitable for controlled or sustained release actives 
4. Allows high drug loading
5. Ability to provide advantages of liquid medication in the form of solid preparation 
6. Adaptable and amenable to existing processing and packaging machinery
7. Cost effective
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        2.3.4 EXCIPIENTS USED FOR IMMEDIATE RELEASE DOSAGE FORMS:
1. Bulking materials: 
Bulking  materials  are  essential  in  the  formulation  of  fast  melting  tablets.  The  bulking
material has the functions of a diluent, filler and cost reducer. Bulking agents improve the
textural characteristics that in turn enhance the disintegration in the mouth, besides; adding
bulk it also reduces the concentration of the active in the composition. 
Eg. Mannitol, polydextrose, lactitol, DCL (direct compressible lactose) and starch
hydrolystate for higher aqueous solubility and good sensory perception.
2. Emulsifying agents:  
Emulsifying agents are important excipients for formulating immediate release tablets they
helps in rapid disintegration and drug release. In addition, incorporating emulsifying agents
is useful in stabilizing the immiscible blends and enhancing bioavailability.
Eg. Alkyl sulfates, propylene glycol esters, lecithin, sucrose and esters 
3. Lubricants: 
Lubricants, though not essential excipients, can further assist in making these tablets more
palatable after they disintegrate in the mouth. Lubricants also remove grittiness and assist in
the drug transport mechanism from the mouth down into the stomach.
Eg. Magnesium Stearate, Talc 
4. Flavours and Sweeteners:
Flavours and  taste-masking  agents  make  the  products  more  palatable  and  pleasing  for
patients. The addition of these ingredients helps in overcoming bitterness and undesirable
tastes of some active ingredients. Both natural and synthetic flavours are used to improve the
organoleptic characteristic of fast melting tablets. The addition of sweeteners contributes a
pleasant taste as well as bulk to the composition.
Eg. Sugar, dextrose, fructose, aspartame, sodium saccharin, sugar alcohols and sucralose. 
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5. Superdisintegrants:
A  disintegrant is an excipient, which is  added to a tablet  or capsule blend to aid in the
breakup of the compacted mass when it is put into a fluid environment. 
Advantages: 
1. Effective in lower concentrations 
2. Less effect on compressibility and flowability 
3. More effective intragranularly 
Mechanism of disintegrants
1) High swellability
2) Capillary action and high swellability
3) Chemical reaction
The most popular  disintegrants  are corn starch,  soluble starch etc.  which have
been well dried and powdered. Starches have great  affinity for water and swell when
moistened thus facilitating the rupture of the tablet matrix, its  disintegration action in
tablets is due to capillary action. Spherical shape of starch increases the porosity of tablet
thus promoting capillary action.
Classification of Super disintegrants may be organized into three classes based on
their chemical structure. As shown in Table 2.3.4.1.
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Table 2.3.4.1:- Classification of  Superdisintegrants.
Structure Type
(NF Name)
Description Trade Name
1. Modified starches
(Sodium starch
glycolate NF)
Sodium carboxy methyl starch,
the carboxymethyl groups
induced hydrophilicity and
cross-linking reduces
solubility.
Explotab
Primojel
2. Modified cellulose
(Croscarmellose
NF)
Sodium carboxy methyl
cellulose which has been
cross-linked to render the
material insoluble.
Ac-Di-Sol
Nymcel
Solutab
3. Cross-linked
polyvinylpyrrolidone
(Crospovidone. NF)
Cross-linked
polyvinylpyrrolidone, the high
molecular weight and cross-
linking render the material
insoluble in water.
Crospovidone
Kollidon
Polyplasdone
       
 2.4 BILAYERED TABLETS9-10 
       Bilayer tablets are composed of two or three layers of granulation compressed together.
They have the appearance of a sandwich because the edges of each layer are exposed.
        Advantages
 This dosage form has the advantage of separating two incompatible materials.
 The weight of each layer can be accurately controlled, in contrast to putting one drug of a
combination product in a sugar coating.
DEPT. of Pharmaceutics, R.V.S College of Pharmaceutical Sciences   Page 10
Introduction
 Two-layer  tablets require fewer materials  than compression coated tablets, weight less,
and may be thinner.
 Monograms and other distinctive markings may be impressed on the surfaces of the multi-
layer tablets. 
 Analytical work may be simplified by separating of the layers prior to assay.
 Since  there  is  no transfer  to  second set  of  punches  and dies,  as  with  the dry-coating
machines,  add  shapes  (such  as  triangles,  squares,  and  ovals)  present  no  operating
problems except for those common tolling.
     Bi-layer tablets are tablet, made by compressing two different granulations fed into a
die succession, one on top of another, in layers. Each layer comes from a separate feed
frame with individual weight control. Rotary tablet press can be set up for two or three
layers. More are possible but the design becomes very special.  Figure 2.4.1 represents
compression cycle of bi-layer tablet
Figure 2.4.1:-Compression cycle of bi-layer tablet.
       Steps of compression of bi-layer tablet:
1. Filling of first layer.
2. Compression of first layer.
3. Ejection of upper punch.
4. Filling of second layer.
5. Compression of both layer together.
6. Ejection of bi-layer tablet.
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    2.5 COATING PROCESS11-13:-
• Tablet coating  
The  application  of  coating  to  the  tablets,  which  is  an  additional  step  in  the
manufacturing process, increases the cost of products; therefore, the decision to coat a
tablet usually based on one or more of the following reasons.
- To mask the taste, odor or color of the tablets
- To provide physical and chemical stability to the drugs
- To control the release of the drug from the tablets
- To protect the drug from gastric environment of the stomach with an acid resistant enteric
coating
- To  incorporate  another  drug  or  formula  adjuvant  in  the  coating  to  avoid  chemical
incompatibilities or to provide sequential drug release
- To improve the pharmaceutical elegance by use of colors and contrast printing
• Types of coating
1. Enteric coating
2. Sugar coating
3. Film coating
2.5.1 Enteric coating
“An enteric coating is a coating system that resists disintegration or dissolution in
gastric media but disintegrates or dissolves in intestinal fluid”.
An enteric protected dosage form is the most common type of delayed release
product. Enteric protection relies on the use of a polymeric material, usually as a coating
which has pH selective solubility, taking advantage of change in pH that occurs as the
dosage form progress through the gastro-intestinal tract.
In developing a drug delivery system for a particular drug candidate, formulation
expertise  to  ensure  the right  choice of  technology early  in  the development  cycle  by
considering such factors as:
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• Physico-chemical properties of the drug
• Physiology of the gastrointestinal  tract  and the manner in which the drug will  be
absorbed during passage  
• Effect of food on the absorption rate and transit time of the drug.
 Reason for enteric protection 
 Prevention of gastric irritation
 e.g. Diclofenac sodium
 Protection of drug unstable in gastric fluid
 e.g. Erythromycin
 Delivery of drug to intestinal site of action 
 E.g. Sulphasalazine
 Delivery of drug to best absorption site
 Delayed drug release
 e.g. Once daily antihistamine
      2.5.2 Sugar Coating
Sugar Coating is now rarely used in pharmaceuticals field because of it’s Skillfull
and tedious process. 
There are various step of sugar coating
1. Seal Coating
2. Sub Coating
3. Syrup (Smoothing/Color) Coating
4. Polishing
2.5.3. Film Coating
Film Coating is  widely used in  pharmaceuticals  to  protect  compressed  tablets
from Light, Heat and Moisture.
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A very even application of the coating material  is  an important  feature  of the
coating process.  Coatings  must be dense and without mechanical  damage and cracks.
Film  coating  is  an  effective  process  for  the  application  of  protective  films  for
manipulating the product characteristics. 
• Film Coating Material
There are following film coating material widely used in the formulation.
Table 2.5.3.1:-List of Film coating materials
Coating
components
Examples
Film  Former
Polymer
Hydroxy Propyl Methyl Cellulose, Ethyl Cellulose, poly vinyl
pyrollidone
Solvents
Water,  ethanol,  methanol,  isopropanol,  chloroform,  acetone,
methylethyl ketone, methylene chloride and more.
Plasticizers
Triethyl citrate, Triacetin, Dibutyl phthalate, Diethyl phthalate,
Castor oil, polyethylene glycol 4000 and 6000.
Colorants
FDA  approved  colors  for  e.g.  quinoline  yellow  lac,  sunset
yellow lac, iron oxide red.
Opaquant-
extenders
Titanium  dioxide,  talc,  aluminium  silicate,  magnesium
carbonate,  calcium sulfate,  magnesium oxide and aluminium
hydroxide.
• Film defect
Variation in formulation and processing conditions may results in unacceptable
quality film coating. These defects are as follows.
- Sticking and Picking
- Roughness
- Orange peel effect
- Twin formation
- Bridging and Filling
- Hazing or dull film
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2.6 EVALUATION OF TABLETS6
The tablets are subjected to the following quality control tests: 
1. Weight variation 
2. Friability 
3. Hardness 
4. Diameter
5. Length/ Width
6. Disintegration 
7. In vitro Dissolution 
8. Stability studies 
       Weight variation: 
The weight variation test is carried out to ensure uniformity in the weight of tablets in a
batch.  The total  weight  of  20 tablets  from each  formulation was  determined  and the
average  weight  was  calculated.  The  individual  weights  of  the  tablets  were  also
determined accurately and the weight variation was calculated. 
Hardness: 
The hardness of tablet is an indication about its strength. Here the force required to break
the tablet is measured. The force is measured in kg and the hardness of about 3-5 kg/cm2
is considered to be satisfactory for uncoated tablets. Hardness of 10 tablets from each
formulation was determined by Monsanto hardness tester. 
Friability test: 
Friability  is  the  loss  in  the  weight  of  tablet  in  the  container  due to  removal  of  fine
particles from the surface. Friability test is carried out to find the ability of the tablet to
withstand abrasion in packaging, handling and transport. Roche friabilator was employed
for finding the friability of the tablets. 20 tablets from each formulation were weighed
and placed in Roche friabilator that rotated at 25 rpm for 4 minutes. The tablets were
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dedusted and weighed again. The percentage of weight loss was calculated again. The
percentage of weight loss was calculated using the formula 
% Friability = [(W1-W2)100]/W1 
Where, 
W1= Weight of tablet before test 
W2 = Weight of tablet after test 
Disintegration test: 
The USP device to test disintegration is six glass tubes that are 3cm long, open at the top,
and held against 10# screen at the bottom end of the basket rack assembly. One tablet is
placed in each tube and the basket rack is positioned in 1 litre beaker of distilled water at
37± 2  ˚ C, such that the tablets remain below the surface of the liquid on their upward
movement and descend not closer than 2.5cm from the bottom of the beaker. 
         IN VITRO DRUG RELEASE STUDIES
The immediate release tablets are subjected to in vitro drug release studies in 0.1N HCl
for  30 minutes  to access  the ability of the formulation for  providing immediate drug
delivery. 
Drug  release  studies  were  carried  out  in  eight  stage  dissolution  test  apparatus  using
specified volume of dissolution media maintained at 37±10c. The tablets are kept in the
cylindrical basket and rotated at 100 rpm ,5ml of the sample from the dissolution medium
are  withdrawn  at  each  time  interval  (2,  3,  5,  10,  15&30  minutes)  and  5ml  of  fresh
medium was replaced each time. The samples were filtered and from the filtrate 1ml was
taken and diluted to 10ml. 
In vitro dissolution kinetic studies
The  drug  release  data  were  plotted  and  tested  with  zero  order  (Cumulative  % drug
released Vs time), First order (Log %Remained Vs time). The zero order release kinetics
was shown in Figures. The First order release kinetics were shown in figures. The in vitro
dissolution kinetic parameters, dissolution rate constants (K), correlation coefficient ®,
the  times  (t50)  for  50%  drug  released  (half  life)  and  dissolution  efficiency  were
DEPT. of Pharmaceutics, R.V.S College of Pharmaceutical Sciences   Page 16
Introduction
calculated and presented in the tables of following chapters.  From the slope of linear
plots, the dissolution rates were calculated. 
First – order release kinetics
logQ1 = logQo + k1t 2.303
The  First  order  equation  describes  that  the  release  from  systems  is  concentration
dependent. Where Qo is the initial amount of the drug, t is in minutes and k1 describes the
dissolution rate constant for first order release kinetics. A plot of the logarithm of the
percent drug remained against time will be linear if the release obeys first- order release
kinetics. Values of release rate constant k1  were obtained in each case from the slope of
the log % drug remained versus time plots.
Dissolution efficiency 
DE is defined as the area under the dissolution curve up to the time ‘t’ expressed as a
percentage of the area of the trapezoid described by 100% dissolution in the same time. 
DE = t d y.dt Yidd.t
      2.7 REVERSE-TRANSCRIPTASE INHIBITORSS26
      2.7.1 INTRODUCTION
Reverse-transcriptase inhibitors (RTIs) are a class of antiretroviral drug that used to treat
HIV infection, tumors and cancer. RTIs inhibit activity of reverse transcriptase, a viral
DNA polymerase enzyme that retroviruses required to reproduce.
        2.7.2 MECHANISM
When HIV  infects  a  cell,  reverse  transcriptase  copies  the  viral  single  stranded  RNA
genome into a double-stranded viral DNA. The viral DNA is then integrated into the host
chromosomal DNA, which then allows host cellular process, such as transcription and
translation to reproduce the virus. RTIs block reverse transcriptase’s enzymatic function
and prevent completion of synthesis of the double-stranded viral DNA, thus preventing
HIV from multiplying.
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A similar process occurs with other types of viruses. The hepatitis, for example, carries
its  genetic  material  in  the  form  of  DNA,  and  employs  a  RNA-dependent  DNA
polymerase to replicate. Some of the same compounds used as RTIs can also block HBV
replication; when used in this way they are referred to as polymerase inhibitors.
     2.7.3 TYPES
RTIs come in three forms:
• Nucleoside analog reverse-transcriptase inhibitors (NARTIs or NRTIs)
• Nucleotide analog reverse-transcriptase inhibitors (NtARTIs or NtRTIs)
• Non- nucleoside reverse-transcriptase inhibitors (NNRTIs)
The mode of action of NRTIs and NtRTIs is essentially the same; they are analogues of
the naturally occurring deoxynucleotides required to synthesize the viral DNA and they
compete with the natural deoxynucleotides for incorporation into the growing viral DNA
chain. However, unlike the natural deoxynucleotides substrates, NRTIs and NtRTIs lack a
3'-hydroxyl group on the deoxyribose moiety. As a result, following incorporation of an
NRTI  or  NtRTI,  the  next  incoming  deoxynucleotide  cannot  form  the  next  5'-3'
phosphodiester bond needed to extend the DNA chain. Thus, when an NRTI or NtRTI is
incorporated, viral DNA synthesis is halted, a process known as chain termination. All
NRTIs and NtRTIs are classified as competitive substrate inhibitors.
In contrast, NNRTIs have a completely different mode of action. NNRTIs block reverse
transcriptase  by  binding  at  a  different  site  on  the  enzyme,  compared  to  NRTIs  and
NtRTIs.  NNRTIs  are  not  incorporated  into  the  viral  DNA  but  instead  inhibit  the
movement of  protein domains of  reverse transcriptase that are needed to carry out the
process of DNA synthesis. NNRTIs are therefore classified as non-competitive inhibitors
of reverse transcriptase.
     2.7.3.1  NUCLEOSIDE  ANALOG  REVERSE-TRANSCRIPTASE  INHIBITORS
(NARTIS OR NRTIS) 
Nucleoside analog reverse-transcriptase inhibitors (NARTIs or NRTIs) compose the first
class of antiretroviral drugs developed. In order to be incorporated into the viral DNA,
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NRTIs must be activated in the cell by the addition of three  phosphate groups to their
deoxyribose moiety, to form NRTI triphosphates. This phosphorylation step is carried out
by cellular kinase enzymes.
Eg.Zidovudine, Didanosine, Zalcitabine, Stavudine, Lamivudine, Abacavir, Emtricitabine
Entecavir and Apricitabine
2.7.3.2 NUCLEOTIDE ANALOG REVERSE-TRANSCRIPTASE INHIBITORS (NTARTIS 
OR NTRTIS)
Normally, nucleoside analogs are converted into nucleotide analogs by the body. Taking
nucleotide analog reverse-transcriptase inhibitors (NtARTIs or NtRTIs) directly allows
conversion steps to be skipped.
Eg. Tenofovir,  Adefovir 
     2.7.3.3 NON-NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITORS (NNRTIS)
Non-nucleoside  reverse-transcriptase  inhibitors  (NNRTIs)  are  the  third  class  of
antiretroviral drugs that were developed. In all cases, patents remain in force until beyond
2007.
Eg. Efavirenz, Nevirapine, Delavirdine, Etravirine
2.7.4  MECHANISMS  OF  RESISTANCE  TO  REVERSE-TRANSCRIPTASE
INHIBITORS 
While NRTIs and NNRTIs alike are effective at terminating DNA synthesis and HIV replication,
HIV can and eventually does develop mechanisms that confer the virus resistance to the drugs.
HIV-1 RT does not have proof-reading activity, this combined with selective pressure from the
drug leads to mutations in reverse transcriptase that make the virus less susceptible to NRTIs and
NNRTIs. Aspartate residues 110, 185, and 186 in the reverse transcriptase polymerase domain
are important in the binding and incorporation of nucleotides. The side chains of residues K65,
R72,  and  Q151  interact  with  the  next  incoming  nucleotide.  Also  important  is  L74,  which
interacts with the template strand to position it for base pairing with the nucleotide. Mutation of
these key amino acids results in reduced incorporation of the analogs.
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2.7.4.1NRTI RESISTANCE
There  are  two  major  mechanisms  of  NRTI  resistance.  The  first  being  reduced
incorporation of the nucleotide analog into DNA over the normal nucleotide. This results
from mutations in the N-terminal  polymerase domain of the reverse transcriptase that
reduce the enzyme’s  affinity or ability to bind to the drug.  A prime example for this
mechanism is  the  M184V mutation  that  confers  resistance  to  lamivudine  (3TC)  and
emtricitabine (FTC). Another well characterized set of mutations is the Q151M complex
found in multi-drug resistant HIV which decreases reverse transcriptase’s efficiency at
incorporating NRTIs, but does not affect natural nucleotide incorporation. The complex
includes  Q151M mutation  along  with  A62V,  V75I,  F77L,  and  F116Y.  A virus  with
Q151M  alone  is  intermediately  resistant  to  zidovudine  (AZT),  didanosine  (ddI),
zalcitabine (ddC), stavudine (d4T), and slightly resistant to abacavir (ABC). A virus with
Q151M complexed with the other four mutations becomes highly resistant to the above
drugs,  and is  additionally resistant  to lamivudine (3TC) and emtricitabine (FTC). The
second mechanism is the excision or the hydrolytic removal of the incorporated drug or
pyrophosphorlysis.  This  is  a  reverse  of  the  polymerase  reaction  in  which  the
pyrophosphate/PPI released during nucleotide incorporation reacts with the incorporated
drug (monophosphate) resulting in the release of the triphosphate drug. This ‘unblocks’
the  DNA  chain,  allowing  it  to  be  extended,  and  replication  to  continue.  Excision
enhancement  mutations,  typically  M41L,  D67N,  K70R,  L210W,  T215Y/F,  and
K219E/Q, are selected for by thymidine analogs AZT and D4T; and are therefore called
thymidine analog mutations (TAMs). Other mutations including insertions and deletions
in the background of the above mutations also confer resistance via enhanced excision.
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3.0 LITERATURE REVIEW
1. The United state pharmacopoeia (2009): USP reports the use of dissolution media
such as 0.1N HCl as official media for drug Tenofovir DF and the maximum wave length
was 260nm in their respective monographs34.
2. B .Praveenreddy et al; (2011): studied on formulation and evaluation of immediate
release  efavirenz,  Tenofovir  DF  and  Lamivudine  bilayer  tablets  by  using  2%  SLS  as
dissolution medium.Here the SLS in efavirenz layer  is  incompatible with Tenofovir DF.
Here wet granulation method was used for granulation16.
3. Syeed  azeem  et  al;  (2011):  studied  on  the  immediate  release  delivery  system.
According to him the  basic approach  in development of immediate tablets is the use of
superdisintegrants  like  Cross  linked  carboxymethylcellulose,  Sodium  starch  glycolate,
Polyvinylpyrrolidone  etc. which provide rapid disintegration of tablet after administration.
A wide range of drugs can be considered candidates for this dosage form6.
4.   Bytul M.Rahman et al; (2008):  studied on effect  of starch 1500 as a binder and
disintegrant  in  Lamivudine  tablets  prepared  by  high  shear  wet  granulation. Fully
pregelatinized starch is currently being used as binder in wetgranulated formulations. But
due  to  the  gelatinization,  much  of  the  disintegration  properties  are  lost.  Partially
pregelatinized starches (Starch 1500) have a mixture of properties of both native and fully
gelatinized starches made them useful both as a binder and disintegrant in wet granulated
formulations. Starch 1500 performed as an excellent binder producing a granulation that was
compressible  and  produced  Lamivudine  tablets  of  improved  hardness  and  friability
compared with those prepared with povidone17.
5. Varun Dasari et al; (2010):  studied on formulation and evaluation of Lamivudine
multiunit  floating  dosage  forms  using  noval  lipoidal  polymers.  Here  he  compared  the
dissolution characteristics of his optimized formulation with that of the pure drug and the
marketed formulation18.
6. Ramesh et al; (2010): studied on the formulation and evaluation of the Bi-Layered
sustained release matrix tablets of Metformin HCl SR and Pioglitazone.The tablets were
prepared  using  sodium  carboxymethylcellulose(SCMC)  and  Hydroxypropyl  Methyl
cellulose  (HPMC K4M & HPMC 15cps)  as  bio-adhesive  polymers  and  croscarmellose
sodium to act as an impermeable backing layer19.   
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7. Shirkhedkar  Atul  A  et  al;  (2009:  studied  on  the  application  of  UV-
Spectrophotometric methods for estimation of Tenofovir DF in tablets. Here Tenofovir DF
was estimated at 260nm in 0.1N HCl.It showed amplitude at 273nm20.
8.     Alexander Kuo  et  al;  (2004):  studied  on  Tenofovir  DF  for  the  treatment  of
Lamivudine resistant hepatitis B. The addition of Tenofovir DF  to the existing regimen of
Lamivudine   resulted in a  median decline of  4.5  log10 copies/mL in HBV DNA levels
(range, 3.2–6.3 log10 copies/mL) after a median treatment duration of 12 months (range, 6–
16 mo). No significant adverse events were encountered during treatment.  In patients with
Lamivudine -resistant hepatitis B, treatment with Tenofovir DF is well tolerated and results
in  significant  virological,  serological,  and  biochemical  improvements  without  the
complication of renal toxicity29.
9. Prasanna A Nevase et al; (2011): studied on UV spectrophotometric method for
estimation of Tenofovir Disoproxil fumarate tablet dosage form. They found a simple, rapid
and  accurate  method  for  quantitative  estimation  of  Tenofovir  DF  .They  found  that  in
methanol Tenofovir show maximum absorbance at 260nm30.
10.   Defang et al; (2005):  Formulate bi-layer tablet of Metformin and Glipizide.  They
conclude that extended release formulations exhibiting comparable in-vitro release profiles
using  two  formulation  principles,  i.e.,  elementary  osmotic  pump  tablets  and  bi-layer
hydrophilic matrix tablet21.
11.   Bhavesh Shiyani  et  al;  (2008):  Formulate  bi-layer  tablet  of  Metoclopramide
Hydrochloride  (MTH)  and  Ibuprofen  (IB)  for  the  effective  treatment  of  migraine.  Here
MTH and IB were formulated as immediate release and sustained release layer respectively.
MTH  was  formulated  as  immediate  release  layer  by  using  various  disintegrants  like
Ac.Di.Sol22.
12.    Althaf A.S. et al; (2010): prepared sustained release matrix tablets of Lamivudine to
increase its bioavailability. The tablets were prepared by direct compression technique using
polymers such as HPMC E15 & EC alone or in combination and other standard excipients.
A factorial design was applied to systematically optimize the drug release profile. Optimized
formulation shows release up to 16 hours as it fulfills all the requirements for sustained drug
delivery system23.
13.  Prakash K. et al; (2007):  formulate microcapsules of Lamivudine by using polymer
such as CAP, CAB, EC & HPMCP to improve the release profile of drug. It is prepared by
solvent  evaporation  technique.  A  factorial  design  was  used  to  elucidate  the  effect  of
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variables viz. amount of drug release & the amount of polymer. The microcapsules were
capapable for releasing drug more than 12 hrs & reducing frequency of administration24.
14. Nayak B.S et al; (2009): developed micro sphere of Lamivudine by using Modified
solvent  evaporation  technique  & enteric  polymer  such as  Acryl  coat,  L30D & S100 to
improv the release profile of drug. A factorial design was used to elucidate the effect of
variables viz. amount of drug release & the amount of polymer. Plasma concentration was
maintained  above  the  minimum  effective  concentration  for  longer  time  after
administration25.
15. Tiwari A.K et al; (2011): Formulated and evaluvated immediate release tablets of
Drotaverine HCl. Wet granulation method was used because oof very high flow of powder
blend that might create the problem of uneven dye filling. The superdisintegrant AC-Di-Sol
and crospovidone were used for immediate release of drug from tablet26. 
16. Arkhel Alka et al; (2011): Formulated and evaluated sustained release matrix tablet
of Lamivudine using tamarind seed polysaccharide. The main aim of proposed is to focus on
the  possibilities  of  using  polysaccharide  in  industries  with  particular  reference  to  its
physical, chemical properties for the formulation of new drug delivery systems27.
17.  Pranitha Yeluri et al; (2010):  Formulated and evaluated controlled release matrix
tablet of Lamivudine using different proportion of guar gum as the retardant polymer and to
study the effect of formulation factor such as polymer proportion on the invitro release of
drug28.
18. S.  Tamizhrasi  et  al;  (2009): Formulated  and  evaluated  Lamivudine  loaded
polymethacrylic  acid  nanoparticles.The  aim  of  the  study  was  to  prepare  and  evaluate
polymethacrylic acid nanoparticles containing lamivudine in different drug to polymer ratio
by nanoprecipitation method31.
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4. Aim and Objective
The concept of the immediate release tablets are formulated from past several years. The
nucleoside and nucleotide analog reverse transcriptase inhibitors are the drugs used for HIV
patients. These drugs should be given along with another nucleoside or nucleotide analog
reverse  transcriptase  inhibitors.  Single  drug  therapy  is  not  suited because  if  the  drug  is
giving as  single dose for  long term eventually the HIV virus  develops resistance  to the
drugs.  So the drugs have to be given in combination. Here the aim was to combine two
Tenofovir DF and Lamivudine which are available in the market as single dose immediate
release tablets. So the patients don’t have to take two tablets. It will also reduce the cost of
the tablet.  Conventional  method is  (immediate release  tablets)  best  method to formulate
Tenofovir  Df  and  Lamivudine  tablets.  The  concept  of  immediate  release  attained  by
maintaining more than 50% drug loaded formulation by incorporating the superdisintegrants
and binder,  optimization of concentrations of those in the formulation to maintain faster
disintegration time for faster drug dissolution profile.
                                                                                                                            
 Tenofovir DF is a Nucleotide reverse transcriptase inhibitor, usually administered at
doses of 300 mg per day. 
 Lamivudine is a Nucleoside reverse transcriptase inhibitor, usually administered at
doses of 300 mg per day.
 The  pharmacokinetic  and  pharmacodynamics  of  the  drug  makes  it  suitable  for
administration through oral route
 The formulation of Tenofovir DF and Lamivudine in the form of oral tablets is a
satisfactory tool to achieve its best therapeutic efficacy, since it is well absorbed and well
tolerated through out the GI tract.
 The  formulation  of  Tenofovir  DF  &  Lamivudine  bilayer  film  coated  tablets
improves its appearance and aids in good patient compliance. The immediate effect of these
tablets enhances the onset time of action of the drug
Hence, the aim of the present work is to formulate immediate release film coated tablets of
an Tenofovir DF and Lamivudine. The formula is optimized with various concentrations of
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excipients and the method of preparation (Wet granulation) can be selected by performing
pilot  trial  studies.  The  physical  parameters  evaluation,  in-vitro  drug  release  studies  are
conducted to justify the formulation efficacy.
4.1 Objective: 
 Formulation and evaluation of combination of immediate release tablets of Tenofovir DF 
and Lamivudine.
 Improvement of the drug dissolution profile.
 To  study  the  effect  of  super  disintegrant  concentration  on  the  dissolution  profiles  of
drug containing formulations.
 To study the effect of different granulation and formulation methods on dissolution profiles
of drug.
 To  determine  the  chemical  compatibility  of  formulation  containing  various  ratio  of
polymer and drug.
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5. DRUG PROFILE
5.0 DRUG PROFILE OF TENOFOVIR DISOPROXIL FUMARATE36-42
 DRUG NAME : TENOFOVIR DISOPROXIL FUMARATE
 CHEMICAL NAME :Bis(1-methyl-ethyl)ester-(R)-5-[[2-(6-Amino-9H-purin- 9-
yl)-1-methylethoxy]methyl]-2,4,6,8-tetraoxa-5-phosphanonanedioic  acid  5-oxide(E)-2-
butenedioate
 CATEGORIES : Anti-HIV Agents
 BCS CLASSIFICATION : Class-III
 PHYSIOCOCHEMICAL PROPERTIES:
           Molecular Structure               :     
        Appearance              : Tenofovir DF is white to off-white crystalline powder.  
 Solubility  : Soluble in water, slightly soluble in alcohol;
  sparingly soluble in methyl alcohol.
 Formula                      : C19H30N5O10P •C4H4O4
 Mol.Mass                    : 635.5 g/mol
Odour                          :Odourless
Melting Point               :114°C-118°C
pH                                :3.14 (1% aqueous solution)
pKa                              :6.14 (0.1g in 60% of DD Water)
Log P                           :0.78 (Organic Phase: Octanol, Aqueous phase: Water)
Cmax                           : 0.3mcg.h/ml
Tmax                           : 1 hour
Bioavliabilty                : 25%
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 MECHANISM OF ACTION:
Tenofovir DF  inhibits the activity of HIV reverse transcriptase by competing with the
natural substrate deoxyadenosine 5’-triphosphate after incorporation into DNA, by DNA
chain  termination.  Specifically,  the  drugs  are  analogues  of  the  naturally  occuring
deoxynucleotides need to synthesize the viral DNA and they compete with the natural
deoxynucleotides for incorporation into the growing viral DNA chain. However, unlike
the  natural  deoxynucleotides  substrates,  NRTIs  and  NtRTIs  (nucleoside/tide  reverse
transcriptase inhibitors) lack a 3'-hydroxyl group on the deoxyribose moiety. As a result,
following incorporation of an NRTI or an NtRTI,  the next incoming deoxynucleotide
cannot form the next 5'-3' phosphodiester bond needed to extend the DNA chain. Thus,
when an NRTI or NtRTI is incorporated, viral DNA synthesis is halted, a process known
as  chain  termination.  All  NRTIs  and  NtRTIs  are  classified  as  competitive  substrate
inhibitors.
 PHARMACOKINETICS:
• Absorption  and Bioavailability: The  oral  bioavailability  in  fasted  patients  is
approximately 25%. Administration of food (high fat meal containing 40 to 50%
fat)  increases  the  oral  bioavailability,  with  an  increase  in  the  AUC  of
approximately 40%.
•      Distribution: 
                1.3 ± 0.6 L/kg [Tenofovir DF 1.0 mg/kg] 
    1.2 ± 0.4 L/kg [Tenofovir DF 3.0 mg/kg]
• Metabolism:  Neither  Tenofovir  disoproxil  nor  Tenofovir  are  substrates  of
CYP450 enzymes.
•  Excretion Renal (70% - 80%)
 HALF LIFE : Approximately 17 hours.
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 USES: 
Treatment of HIV-1 infection in adults and children 12 y of age and older, in combination
with other antiretroviral agents; treatment of chronic hepatitis B infection in adults. 
 INDICATIONS:
Tenofovir DF is a nucleotide analogue indicated in combination with other antiretroviral
agents for the treatment of human immunodeficiency virus (HIV-1) infection. 
 DOSAGE AND ADMINISTRATION: 
• Adults and Adolescents > 16 years of age
The recommended oral dose of Tenofovir DF in HIV-1-infected adults and adolescents >
16 years of age is 300 mg daily orally without regard to food.
Pediatric Patients
The recommended oral dose of  Tenofovir DF  in HIV-1-infected pediatric patients 12
years of age and older with body weight greater than or equal to 35 kg (greater than or equal to 77
lb): The dose is one 300 mg Tenofovir DF tablet once daily taken orally, without regard to food.
 SIDE EFFECTS: 
Tenofovir DF may cause lactic acidosis (a build-up of lactic acid in the body, which can be 
fatal). Lactic acidosis can start slowly and get worse over time. Get emergency medical help if 
you have even mild symptoms of lactic acidosis, such as: muscle pain or weakness, numb or cold
feeling in your arms and legs, trouble breathing, stomach pain, nausea with vomiting, fast or 
uneven heart rate, dizziness, or feeling very weak or tired. Call your doctor at once if you have a 
serious side effect such as:
• liver damage - nausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored 
stools, jaundice (yellowing of the skin or eyes);
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• kidney problems - increased thirst and urination, loss of appetite, weakness, constipation, 
urinating less than usual or not at all;
• fever, chills, body aches, flu symptoms; or
• any other signs of new infection.
 PRECAUTIONS:
 Before taking Tenofovir DF, tell your doctor or pharmacist if you have allergy to
it; or if you have any other allergies. 
 Before taking this medication, tell your doctor or pharmacist about your medical
history,  especially of pancreatitis, kidney problems, liver problems and alcohol
use. 
 Avoid alcoholic beverages because they may increase the risk for liver problems
and pancreatitis. 
 This drug may make you dizzy. Do not drive, use machinery or any activity that
requires alertness until you are sure that you can perform such activities safely.
 To decrease the risk of spreading HIV disease to others, always use an effective
barrier method during all sexual activity. 
 Care to be taken while using this drug in children because they may be more
sensitive to the effects of the drug, especially the increased risk of pancreatitis. 
 Kidney function declines as you grow older. This medication is removed by the
kidneys. Avoid use in patients who have recently received nephrotoxic drugs. 
 Tenofovir DF passes into breast milk. Because breast milk can transmit HIV, do
not breast-feed.
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5.1 DRUG PROFILE OF LAMIVUDINE36-42
 DRUG NAME : LAMIVUDINE
 CHEMICAL NAME :4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-
yl]-1,2-dihydropyrimidin-2-one
 CATEGORIES : Anti-HIV Agents
 BCS CLASSIFICATION    : Class-III
 PHYSIOCOCHEMICAL PROPERTIES:
 Molecular structure         : 
  Appearance                     : White or almost white amourphos Powder
 Solubility                     : Soluble in water, slightly soluble in alcohol;
sparingly soluble in methyl alcohol
  Formula         : C8H11N3O3 S 
  Mol Mass                         :   229.26 g/mol 
               Appearance                     : White to off white solid
               Odour                              : Odourless
                Melting Point                 : 172°C-178°C
                 pH                                  : 7.01 (1% aqueous solution)
                pKa                                 : 9.48 (0.1g in 60% of DD Water)
                Log P                              : 0.89 (Organic Phase: Octanol, Aqueous phase: Water)
                Cmax                              : 1.28mcg.h/ml
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                 Tmax                             : 0.5 to 2hour
                 Bioavliabilty                 : 87%
 MECHANISM OF ACTION:
Lamivudine is a synthetic nucleoside analogue and is phosphorylated intracellularly to its
active 5'-triphosphate metabolite,  Lamivudine triphosphate (L-TP). This nucleoside analogue is
incorporated into viral DNA by HIV reverse transcriptase and HBV polymerase,  resulting in
DNA chain termination.
 PHARMACOKINETICS:
• Absorption  and Bioavailability: Lamivudine was  rapidly  absorbed  after  oral
administration in HIV-infected patients. Absolute bioavailability in adults is 86%
± 16% for the tablet and 87% ± 13% for the oral solution. 
• Distribution:  The  apparent  volume  of  distribution  after  IV  administration  of
NL004 to 20 patients was 1.3 ± 0.4 L/kg, suggesting that Lamivudine distributes
into extravascular spaces. Volume of distribution was independent of dose and did
not correlate with body weight.
• Metabolism: The only detected metabolite of Lamivudine is trans-sulfoxide.
• Elimination:  The primary routes of elimination of abacavir are metabolism by
alcohol dehydrogenase to form the 5′-carboxylic acid and glucuronyl transferase
to form the 5′-glucuronide. Lamivudine is excreted in human breast milk. 
 HALF LIFE : 5 to 7 hours
 USES: 
This drug is  used with other medications to help control your  HIV infection,  thereby
improving your quality of life. It may also lower your risk of complications from HIV (such as
new infections, cancers).  Lamivudine belongs to a class of drugs known as nucleoside reverse
transcriptase inhibitors-NRTI. 
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Lamivudine is not a cure for HIV and it does not prevent the spread of HIV to others
through sexual contact or blood contamination (such as sharing used needles). 
 OTHER USES:
This  drug  may  be  used  to  prevent  HIV  infection  after  contact  with  the
virus. A lower-strength Lamivudine E product is used for hepatitis B infection in people without
HIV infection.
 INDICATIONS:
Lamivudine is a nucleoside analogue indicated in combination with other  antiretroviral
agents for the treatment of human immunodeficiency virus (HIV-1) infection. Limitation of use:
The dosage of this product is for HIV-1 and not for HBV.
 DOSAGE AND ADMINISTRATION: 
• Adults and Adolescents > 16 years of age
The recommended oral dose of Lamivudine in HIV-1-infected adults and adolescents >
16 years of age is 300 mg daily, administered as either 150 mg twice daily or 300 mg once daily,
in  combination  with  other  antiretroviral  agents.  If  Lamivudine is  administered  to  a  patient
infected with HIV-1 and HBV, the dosage indicated for HIV-1 therapy should be used as part of
an appropriate combination regimen 
• Pediatric Patients
The recommended oral dose of  Lamivudine Oral Solution in HIV-1-infected pediatric
patients 3 months to 16 years of age is 4 mg/kg twice daily (up to. a maximum of 150 mg twice a
day), administered in combination with other antiretroviral agents.
 SIDE EFFECTS: 
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Headache,  dizziness,  nausea,  diarrhea,  or trouble sleeping may occur.  If  any of  these
effects persist or worsen, notify your doctor or pharmacist promptly.
Changes  in  body  fat  (such  as  increased  fat  in  the  upper  back  and  stomach  areas,
decreased fat in the arms and legs) may occur while you are taking HIV medication. The cause
and long-term effects of these changes are unknown. Discuss the risks and benefits of therapy
with your doctor, as well as the possible role of exercise to reduce this side effect.
A very serious allergic reaction to this drug is rare. However, seek immediate medical
attention  if  you  notice  any  symptoms  of  a  serious  allergic  reaction,  including:  rash,
itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
 PRECAUTIONS:
 Before taking Lamivudine tell your doctor or pharmacist if you have any allergy
to it; or if you have any other allergies. 
 Before using this medication, tell your doctor or pharmacist about your medical
history, especially of: pancreatitis, kidney problems, liver problems, alcohol use. 
 Avoid alcoholic beverages because they may increase your risk for liver problems
and pancreatitis. 
 This drug may make you dizzy. Do not drive, use machinery or do any activity
that requires alertness until you are sure you can perform such activities safely. 
 To decrease your risk of spreading HIV disease to others, always use an effective
barrier method during all sexual activity. 
 Care to be taken while using this drug in children because they may be more
sensitive to the effects of the drug, especially the increased risk of pancreatitis. 
 Kidney function declines as you grow older. This medication is removed by the
kidneys. . Avoid use in patients who have recently received nephrotoxic drugs.
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 Lamivudine passes into breast milk. Because breast milk can transmit HIV, do not
breast-feed.
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6. EXCIPIENT PROFILE34
6.1  LACTOSE MONOHYDRATE
Non-proprietary names – lactose Monohydrate (BP), Lactosum monohydricum (Ph.            
Eur), Lactose (J.P), Lactose Monohydrate (USPNF).
Synonym - Lactochem, Pharmatose, NF lactose, Capsulac, Prismalac, Sorbolac, Sachelac, 
Inhalac, Tablettose, Monohydrate lactose.
Chemical name: O-β-D-galactopyranosyl-(1-4)-β-D Glucopyranose anhydrous ,O-β-D-
galactopyranosyl-(1-4)-β-D Glucopyranose monohydrate. 
Empirical Formula - - C12H22O11, C12H22O11. H2O
Molecular weight – 342.30,360.31
Structural Formula – 
Functional category – binding agent, diluents for only powder inhalers, tablet binder, tablet 
and capsule diluents.
      Applications in pharmaceutical formulations – 
 Lactose monohydrate of various grades can be chosen for various applications. 
 It is widely used as a filler or diluent in tabelts and in capsules
 It is also used in lyophilized products, to increase plug size and aid cohesion.
 Lactose in combination with sucrose (1:3) is to prepare sugar coating solutions.
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 Direct compression grades are available as granulated/agglomerated and α-lactose
monohydrate containing small amounts of anhydrous lactose.
Description – White to off-white crystalline particles of powder. It is odorless and 
slightly sweet tasting. The α-lactose is 20% sweet as sucrose; β lactose is 40% sweet as 
sucrose. Several different forms of lactose are commercially avaliable.
Incompatibilities – Condensation reactions are likely to occur between lactose and 
amino groups and incompatible with amino acids, aminophylline and lisinopril.
Safety - Adverse reactions to lactose are largely due to lactose intolerance, which occurs 
in individuals with a deficiency of the intestinal enzyme lactase.This results in lactose 
being undigested and may lead to clinical symptoms including abdominal 
cramps,diarrhea,distension and flatulence.
Storage/stability - Lactose develops a dark brown coloration on long storage, the 
reaction being accelerated by warm damp conditions. Mould growth may occur at humid 
conditions. It should be stored in a well closed container in a cool, dry place.
6.2 CROSCARMELLOSE SODIUM
Nonproprietary Names- BP: Croscarmellose sodium; PhEur: Carmellosum natricum 
conexum; USPNF: Croscarmellose sodium                                                                           
 synonyms - Ac-Di-Sol; cross linked carboxymethylcellulose sodium; Explocel; modified
cellulose gum; Nymcel ZSX; Pharmacel XL; Primellose; Solutab; Vivasol.
Functional Category -Tablet and capsule disintegrant.
Chemical name – Cellulose carboxymethyl ether calcium salt.
Empirical  Formula  and  Molecular  Weight  -  The  USPNF  23  describes
carboxymethylcellulose  calcium  as  the  calcium  salt  of  polycarboxymethyl  ether  of
cellulose.
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Structural Formula:
Applications in Pharmaceutical Formulation or Technology:
 Used as a disintegrant for capsules, tablets, and granules.
  Croscarmellose  sodium may be used in both direct-compression and wet-granulation
processes in tablet formulations. 
 Wicking  and  swelling  ability  of  the  disintegrant  is  best  utilized  when  used  in  wet
granulations.
 Used both the wet and dry stages of the process (intra and extra granularly). 
 Croscarmellose  sodium  at  concentrations  up  to  5%  w/w  may  be  used  as  a  tablet
disintegrant, 2% w/w is used in tablets prepared by direct compression and 3% w/w in
tablets prepared by a wet-granulation process.
Table no 6.2.1 .Uses of Croscarmellose Sodium:
Description:  Croscarmellose  sodium  occurs  as  an  odorless,  white  or  greyish-white
powder.
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Disintegrant in 
capsule
10-25
Disintegrant in 
tablets
0.5-5.0
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Incompatibilities
The efficacy of disintegrants, such as Croscarmellose sodium, may be slightly reduced in 
tablet formulations prepared by either the wet granulation or direct compression process 
that contain hygroscopic excipients such as sorbitol. 
Croscarmellose sodium is not compatible with strong acids or with soluble salts of iron 
and some other metals such as aluminum, mercury and zinc.
Stability and Storage Conditions
Croscarmellose sodium is a stable though hygroscopic material. Croscarmellose sodium  
should be stored in a well closed container in a cool, dry place.
      6.3 CELLULOSE, MICROCRYSTALLINE
Nonproprietary Names:  BP: Microcrystalline cellulose; JP: Microcrystalline cellulose;
PhEur: Cellulosum microcrystallinum; USPNF: Microcrystalline cellulose
Synonyms:  Avicel  PH;  Celex;  cellulose  gel;  Celphere;  Ceolus  KG;  crystalline
cellulose; E460;Emocel; Ethispheres; Fibrocel; Pharmacel; Tabulose; Vivapur.
Chemical Name - Cellulose [9004-34-6]
Empirical formula – (C6H10O5)n
Molecular weight – n=220 to 36000
          Molecular structure – 
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Functional Category: Adsorbent, Suspending agent, tablet and capsule diluents, tablet 
disintegrant.
Applications in Pharmaceutical Formulation or Technology
 Microcrystalline cellulose is widely used as a binder/diluent in oral tablet and capsule
formulations where it is used in both wet-granulation and direct-compression processes.
 Also has some lubricant and disintegrant properties that make it useful in tableting. 
 it is also used in cosmetics and food products
Table no 6.3.1: Uses of microcrystalline cellulose:
USE CONCENTRATION (%)
Adsorbent 20-90
Anti-adherent 5-20
Capsule binder/diluent 20-90
Tablet disintegrants 5-15
Tablet binder/diluent 20-90
           Description
Microcrystalline cellulose is purified, partially depolymerized cellulose that occurs as a 
white, odorless, tasteless, crystalline powder composed of porous particles. It is 
commercially available in different particle sizes and moisture grades that have different 
properties and applications.
Incompatibility – Microcrystalline Cellulose is incompatible with strong oxidizing 
agents.
Safety – Microcrystalline cellulose is widely used in oral pharmaceutical formulations 
and food products and is generally regarded as a relatively non-toxic and non-irritant 
material. Microcrystalline cellulose is not absorbed systemically following oral 
administration and thus has little toxic potential. Consumption of large quantities may 
have a laxative effect, although this is unlikely to be a problem when cellulose is used as 
excipient.
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Stability/Storage conditions – Microcrystalline is stable though hygroscopic material. 
The bulk material should be closed in a well-closed container in a cool, dry place.
6.4 SODIUM STARCH GLYCOLATE
Nonproprietary Names
BP: Sodium starch glycolate
PhEur: Carboxymethylamylum natricum
USPNF: Sodium starch glycolate
Synonyms
Carboxymethyl starch, sodium salt; Explosol; Explotab; Glycolys; Primojel; starch 
carboxymethyl ether, sodium salt; Tablo; Vivastar P.
Chemical Name : Sodium carboxymethyl starch.
Empirical Formula and Molecular Weight
The USPNF 23 states that sodium starch glycolate is the sodium salt of a carboxymethyl 
ether of starch.
The PhEur 2005 describes three types of material: Types A and B occurs as the sodium 
salt of a cross-linked partly O-carboxymethylated potato starch, containing 2.8–4.2% and 
2.0–3.4% of sodium respectively. Type C is the sodium salt of a cross-linked by physical 
dehydration, partly O-carboxymethylated starch containing 2.8–5.0% sodium.
Sodium starch glycolate may be characterized by the degree of substitution and 
crosslinking. The molecular weight is typically 5 × 105–1 × 106.
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Structural Formula
                           
Functional Category
Tablet and capsule disintegrant.
 Applications in Pharmaceutical Formulation or Technology
 Sodium starch glycolate is widely used in oral pharmaceuticals as disintegrant in capsule
and tablet formulations. 
 It is commonly used in tablets prepared by either direct compression or wet granulation
processes. 
 The concentration employed in a formulation is between 2% and 8%, with the optimum
concentration about 4%.
  Disintegration occurs  by the rapid uptake of  water  followed by rapid and enormous
swelling. 
  By  use  of  sodium starch  glycolate,  increasing  the  tablet  compression  pressure  also
appears to have no effect on disintegration time. 
 Sodium starch glycolate can also be used as a suspending vehicle. 
Description
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Sodium starch glycolate is a white to off-white, odorless, tasteless, free flowing powder.  
It consists of oval or spherical granules, 30–100 µm in diameter, with some less spherical 
granules ranging from 10–35 µm in diameter.
Incompatibilities
Sodium starch glycolate is incompatible with ascorbic acid.
Stability and Storage Conditions
Tablets made with sodium starch glycolate have good storage properties. Sodium starch 
glycolate is stable. It should be stored in a well closed container in order to protect it from
wide variations of humidity and temperature, which may leads to caking.
The physical properties of SSG remain unchanged for up to 3–5 years if it is stored at 
moderate temperatures and humidity.
6.5 PREGELATINISED STARCH
Nonproprietary Names
BP: Pregelatinised starch
PhEur: Amylum  pregelificatum
USPNF: Pregelatinised starch
Synonyms
Compressible starch;instastarch; Lycatab C; Lycatab PGS; Merigel; National 78-1551; 
Pharma-Gel; Prejel; Sepistab ST 200; Spress B820; Starch 1500 G;Tablitz ; Unipure LD; 
Unipure WG220
Chemical Name : Pregelatinised starch
Empirical Formula and Molecular Weight
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(C6H10O5 )n where n=300-1000
Pregelatinised starch is a starch that has been chemically and/ or mechanically processed 
to rupture all or part of the starch granules and so render the starch flowable and directly 
compressible.
Typically pregelatinised starch contains 5% of free amylose , 15%of free amylopectin , 
and 80% unmodified starch. 
The USPNF 20 does not specify the botanical orgin of the orginal starch , but the PhEur 
2002 specifies that pregelatinized starch is obtained from maize (corn),potato, or rice 
starch.
Structural Formula
Functional Category
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Tablet and capsule diluent; tablet and capsule disintegrant; tablet binder.
 Applications in Pharmaceutical Formulation or Technology
 Pregelatinized starch is a modified starch used in oral capsule and tablet formulations as a
binder , diluent, and disintegrant
 It  is  used  as  a  tablet  binder  in  dry-  compression  processes  and  in  wet  granulation
processes 
Table no 6.5.1. Uses of pregelatinized starch.
Use Concentration  (%)
Diluent (hard gelatin capsules) 5–75
Tablet binder (direct compression) 5–20
Tablet binder (wet granulation) 5–10
Tablet disintegrant 5–10
Description
Pregelatinized starch occurs as a moderately coarse to fine, white to off-white colored 
powder. It is odorless and has a slight characteristic taste.Examination of fully 
pregelatinized starch as a slurry in cold water, under a polarizing microscope, reveals no 
significant ungelatinized granules, i.e., no ‘maltese crosses’ characteristic of the starch 
birefringence pattern. Examination of samples suspended in glycerin shows characteristic
forms depending upon the method of drying used during manufacture: either irregular 
chunks from drum drying or thin plates. Partially pregelatinized starch (e.g., Starch 
1500G and Sepistab ST200) show retention of birefringence patterns typical of 
unmodified starch granules.
Incompatibilities
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Stability and Storage Conditions
Pregelatinized starch is a stable but hygroscopic material, which has to be stored in a well
closed container in a cool and dry place.
      6.6 MAGNESIUM STEARATE
      Nonproprietary Names
BP: Magnesium stearate
JP: Magnesium stearate
PhEur: Magnesii stearas
USPNF: Magnesium stearate
Synonym – Magnesium octadeconate, Octadecanoic acid, Magnesium salt, Stearic acid, 
magnesium salt.
Chemical name – Octadeconic acid magnesium salt.
Empirical formula – C36H70MgO4. 
Molecular weight- 591.34
Composition – The USPNF 23 describes magnesium stearate as a compound of 
magnesium with a mixture of solid organic acids that consists chiefly of variable 
proportions of magnesium stearate and magnesium palmitate (C36H70MgO4). The Ph. Eur 
2005 describes magnesium stearate as a mixture of magnesium salts of different fatty 
acids consisting mainly of stearic acid and in major proportions other fatty acids.
Structural Formula – [CH3 (CH2)16COO]2Mg
Functional category – Tablet and capsule lubricant.
Pharmaceutical Applications –
 Magnesium stearate is widely used in cosmetics, foods and pharmaceutical formulatons.
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  It  is primarily used as a lubricant in capsule and tablet manufacture at concentrations
between 0.25% and 5.0%.
  It is also used in barrier creams.
Description –
 Magnesium stearate is a very fine, white, precipitated or milled, impalpable powder of 
low bulk density, having a faint odor of stearic acid and a characteristic taste. The powder
is greasy to touch and readily adheres to the skin
Incompatibilities – Incompatible with strong acids, alkalis and iron salts. Avoid mixing 
with strong oxidizing materials. Magnesium stearate cannot be used in products 
containing aspirin, some vitamins and most alkaloidal salts.
Safety – Magnesium is generally regarded non-toxic following oral administration. 
However overconsumption of large quantities may cause laxative effect and mucosal 
irritation. No toxicity information is available relating to normal routes of occupational 
exposure.
Stability and storage conditions – Magnesium stearate is stable and should be stored in
a well closed container in a cool and dry place.
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7.  INNOVATOR  PRODUCT CHARACTERIZATION:
Table No.7.1 INNOVATOR PRODUCT CHARACTERIZATION OF TENOFOVIR DF41-44
Sr. No. Particulars Observation
1. Generic name Tenofovir Disoproxil Fumarate Tablets
2. Brand name VIREAD
3. Storage condition Store at 25°C excursions permitted to 15-30°C
4. Embossing / Imprinting
details
GILEAD and 4331 on one side and with 300 on other side.
5. Dosage Form Film coated Tablet
6. Strength 300 mg
7. Category Antiretroviral drug
8. Description The tablets are almond-shaped, light blue, film coated and
deboossed with GILEAD and 4331 on one side and with
300 on other side.
9. Pack Details Bottle with CRC cap of 30 tablets.
10.
Inactive Excipients
Croscarmellose sodium,Lactose monohydrate, magnesium
stearate, microcrystalline cellulose, and pregelatinized
starch. Opadry II Y-30-10671A, which contains FD&C blue
#2 aluminium lake, hydroxypropyl methyl cellulose 2910,
titanium dioxide and triacetin
.
11. Weight (mg) 693.0mg, 696.3mg, 681.6mg, 690.5mg
12. Length (mm) 16.9mm, 16.92mm, 16.92mm
13. Thickness (mm) 5.05mm, 5.08mm, 5.09mm
14. Hardness (kp) 18kp, 19.3kp
15. Disintegration Time 3min 02 sec to 3min 26sec
Table No.7.2 INNOVATOR PRODUCT CHARACTERIZATION OF LAMIVUDINE40-43
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Sr. No. Particulars Observation
1. Generic name Lamivudine Tablets
2. Brand name EPIVIR
3. Storage condition Store at 25°C excursions permitted to 15-30°C
4. Embossing / Imprinting
details
Engraved with “GXEJ7” on one side.
5. Dosage Form Film coated Tablet
6. Strength 300 mg
7. Category Antiretroviral drug
8. Description The tablets are grey modified diamond-shaped, film coated 
tablet engraved with “GXEJ7” on one side and plain on the 
reverse side.
9. Pack Details Bottle with CRC cap of 30 tablets.
10. Inactive Excipients Hydroxypropyl methyl cellulose, magnesium stearate, 
microcrystalline cellulose, poly ethylene glycol, polysorbate
80, sodium starch glycolate, titanium dioxide and black iron
oxide.
11. Weight (mg) 612.7mg, 615.2mg, 621.1mg
12. Length (mm) 17.49mm, 17.62mm, 17.61mm
13. Thickness (mm) 5.67mm, 5.64mm, 5.69mm
14. Hardness (kp) 20.7kp, 23.2kp
15. Disintegration Time 45 sec to 48 sec
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8. PLAN OF WORK
 Preformulation study of API
 Preparation of stable Tenofovir DF and Lamivudine tablets 300mg/300mg.
 Preformulation studies.
 Optimization of concentration of excipients and method of manufacturing
 Coating of core tablets
 Evaluation  of  physical  parameters  like  thickness,  hardness,  friability,  and
disintegration time of tablets.
 Evaluation of In-Vitro drug release of the tablets
 Comparative  study  of   Tenofovir  DF  and  Lamivudine   tablets  with  innovator
sample
 Selection of best formulation on the basis of In vitro drug release
 Stability Studies
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 9. MATERIALS AND EQUIPMENT:
Table no 9.1 List of Materials:
Name of Materials Brand Name / Grade Source
Tenofovir DF IH Hetero Labs
Lamivudine IH Hetero Labs
Croscarmellose sodium         
(primellose)
USPNF DMV-FONTERRA
Lactose monohydrate 
(Pharmatose 200M)
USPNF DMV-FONTERRA
Pregelatinized Starch
(Starch 1500)
USPNF COLORCON
Asia Pvt Ltd
Sodium starch Glycolate 
Type A
USPNF ROUQUETTE
Microcrystalline Cellulose 
(AvicelPH 102)
USPNF FMC Biopolymer
Microcrystalline Cellulose 
(Avicel PH 101)
USPNF FMC Biopolymer
Magnesium Stearate USPNF FERRO
Opadry White IH COLORCON
Asia Pvt Ltd
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Table no 9.2 List of Equipment:
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Name of instrument Model no. Make
Electronic Weighing Balance  
(0.5 – 4100 g)
CPA8201 Sartorius
Analytical Balance     
  (1 to 220g)
BT 2245 Sartorius
Octagonal/ Bin Blender GMP LAB Model Gansons
Rapid Mixer Granulator PNEUMATIC Sainath Bioler
Rapid Dryer TG200 Retsch
Tap Density Tester USP ETD-1020 Electrolab
Analytical Sieve Shaker AS200 Retsch
Electronic Moisture Analyzer MA 150 Sartorius
Tabletting Machine-8 Stn MRT-8 KAMBERT
Bilayer Tableting machine-    
10stn
MRT-10 KARNAVATI
Disintegration Test Apparatus 
USP
ED-2L Electrolab
Friabilator USP EF-2 Electrolab
Vernier Calliper CD-8" CSX Mitutoyo Corporation
Homogenizer RQ130 Remi Motors
Hardness Tester 8M Dr.Schluniger
Mechanical Stirrer RQT-124A Remi Motors
Magnetic stirrer 5MLH Remi Motors
Hot plate H.P Heat control
Pharma R&D Coater Deluxe Ideal Cures
Neocota NEOCOTA - 5D Neo machine
FTIR(Fourier Transform Infra 
Red Spectrophotometer)
IR Prestige-21 Shimadzu Emit Co. Ltd
PH meter PH ME002 Eutech Instruments.
UV-Visible 
Spectrophotometer
UV-1700 Pharmaspec
Shimadzu  Emit 
Co.LTD, Japan
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10. Experimental work
10.1 Preformulation studies
10.1.1 Idenfication tests:
UV spectra: Diluted two drug samples in 0.1N HCl and UV spectrum of its obtained   using
a 1cm cell and scanning from 200 to 400nm. And compare the λ max value with the standard
UV spectrum of Tenofovir DF & Lamivudine.
 IR spectra:  The FT-IR spectrum of pure Tenofovir DF & Lamivudine analyzed for study.
Solubility:  Solubility analysis  carried  out  in different  solvents  like water,  HCl,  Acetone,
ethanol and methanol.
10.1.2 Drug exicipient compatibility studies:
     Drug-Excipient compatibility studies form an important part of Preformulation studies. The
interaction between the drug and excipients are determined after a specific time period by using
suitable analytical technique like FTIR.
Procedure:
1) According to the functional category these excipients were mixed in different ratios with
drug.
2) 1 gram of blend size was taken for the ratio calculation. These mixtures were kept in 40°C /
75 %RH.
3) After  4  weeks,  the  samples  were  withdrawn  and  analyzed  with  respect  to  Physical
observation.
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Table no 10.1.2  Details of Drug exicipient compatibility table:
Name of
drug/excipients Ratio
Test parameters
Initial
Period – 15 & 30 Days
40°C/75%
RH
25°C/60%
RH
Tenofovir DF - Physical
observation
Physical
observation
Physical
observation
Lamivudine - Physical
observation
Physical
observation
Physical
observation
Tenofovir DF 
+Lamivudine -
Physical
observation
Physical
observation
Physical
observation
Tenofovir DF +Lactose 
monohydrate(Pharmatose
200m) 1:2
Physical
observation
Physical
observation
Physical
observation
Tenofovir DF + 
Microcrystalline 
Cellulose(Avicel PH101) 1:2
Physical
observation
Physical
observation
Physical
observation
Tenofovir DF + 
Microcrystalline 
Cellulose(Avicel PH101) 1:2
Physical
observation
Physical
observation
Physical
observation
Tenofovir DF + 
Pregelatinized Starch 
(Starch 1500) 1:0.5
Physical
observation
Physical
observation
Physical
observation
Tenofovir DF+ Sodium 
starch glycolate-A 1:0.5
Physical
observation
Physical
observation
Physical
observation
Tenofovir DF+ 
Croscarmellose 
sodium(Primellose)
1:0.5 Physical
observation
Physical
observation
Physical
observation
Tenofovir DF+ 
Magnesium stearate 1:0.05
Physical
observation
Physical
observation
Physical
observation
Tenofovir DF+ Opadry 
White 1:0.25
Physical
observation
Physical
observation
Physical
observation
Lamivudine +Lactose 
monohydrate(Pharmatose
200m) 1:2
Physical
observation
Physical
observation
Physical
observation
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Lamivudine + 
Microcrystalline 
Cellulose(Avicel PH101) 1:2
Physical
observation
Physical
observation
Physical
observation
Lamivudine + 
Microcrystalline 
Cellulose(Avicel PH101) 1:2
Physical
observation
Physical
observation
Physical
observation
Lamivudine + 
Pregelatinized Starch 
(Starch 1500) 1:0.5
Physical
observation
Physical
observation
Physical
observation
Lamivudine+ Sodium 
starch glycolate-A 1:0.5
Physical
observation
Physical
observation
Physical
observation
Lamivudine+ 
Croscarmellose 
sodium(Primellose)
1:0.5 Physical
observation
Physical
observation
Physical
observation
Lamivudine+ 
Magnesium stearate 1:0.05
Physical
observation
Physical
observation
Physical
observation
Lamivudine+ Opadry 
White 1:0.25
Physical
observation
Physical
observation
Physical
observation
Tenofovir 
DF+Lamivudine 
+Lactose 
monohydrate(Pharmatose
200m)
1:2 Physical
observation
Physical
observation
Physical
observation
Tenofovir 
DF+Lamivudine + 
Microcrystalline 
Cellulose(Avicel PH101)
1:2 Physical
observation
Physical
observation
Physical
observation
Tenofovir DF 
+Lamivudine + 
Microcrystalline 
Cellulose(Avicel PH101)
1:2 Physical
observation
Physical
observation
Physical
observation
Tenofovir 
DF+Lamivudine + 
Pregelatinized Starch 
(Starch 1500)
1:0.5 Physical
observation
Physical
observation
Physical
observation
Tenofovir 
DF+Lamivudine + 
Sodium starch glycolate-
1:0.5 Physical
observation
Physical
observation
Physical
observation
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A
Tenofovir 
DF+Lamivudine + 
Croscarmellose 
sodium(Primellose)
1:0.5 Physical
observation
Physical
observation
Physical
observation
Tenofovir 
DF+Lamivudine + 
Magnesium stearate
1:0.05 Physical
observation
Physical
observation
Physical
observation
Tenofovir 
DF+Lamivudine + 
Opadry White
1:0.25 Physical
observation
Physical
observation
Physical
observation
Tenofovir DF+ Placebo 1:2 Physical
observation
Physical
observation
Physical
observation
Lamivudine+ Placebo 1:2 Physical
observation
Physical
observation
Physical
observation
Tenofovir 
DF+Lamivudine+ 
Placebo
1:2 Physical
observation
Physical
observation
Physical
observation
10.1.3 Preparation of Standard curve:
Preparation of samples for Tenofovir DF20:
      100mg of drug was accurately weighed and dissolved and diluted to 100 ml with 0.1N HCl in
volumetric flask. This was the primary stock solution, contained concentration of 1000 µ g/ml.
From this primary stock solution, 1ml was accurately pipetted out and transferred in to a 100 ml
volumetric flask and volume was made up to 100 ml with Solvent 0.1N HCl which contained the
concentration of 10 µ g/ml.  This is the secondary stock solution.
From secondary stock solution aliquots equivalent to 1, 2, 3, 4, and 5 ml were pipette out in to a
series  of  10  ml  volumetric  flask  and  volume  was  made  up  to  10  ml  with  01N  HCl.  The
absorbance of these solutions was measured against the 01N HCl as blank at 260 nm using UV-
Visible  double  beam  spectrophotometer.  Then  a  calibration  curve  was  plotted  taking
concentration in µ g/ml on X-axis and absorbance on Y-axis.
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Preparation of samples for Lamivudine:
      100mg of drug was accurately weighed and dissolved and diluted to 100 ml with 0.1N HCl in
volumetric flask. This was the primary stock solution, contained concentration of 1000 µ g/ml.
From this primary stock solution, 1ml was accurately pipette out and transferred in to a 100 ml
volumetric flask and volume was made up to 100 ml with Solvent 0.1N HCl which contained the
concentration of 10 µ g/ml.  This is the secondary stock solution.
From secondary stock solution aliquots equivalent to 1, 2, 3, 4, and 5 ml were pipette out in to a
series  of  10  ml  volumetric  flask  and  volume  was  made  up  to  10  ml  with  0.1N HCl.  The
absorbance of these solutions was measured against the 0.1N HCl as blank at 270 nm using UV-
Visible  double  beam  spectrophotometer.  Then  a  calibration  curve  was  plotted  taking
concentration in µ g/ml on X-axis and absorbance on Y-axis.
10.1.4 Preformulation studies of blend:
 Preformulation  testing  is  an  investigation  of  physical  and  chemical  properties  of  a  drug
substance  alone  and  when  combined  with  excipients.  It  is  the  first  step  in  the  rational
development of dosage forms.
Preformulation  commences  when  a  newly  synthesized  drug  shows  sufficient  pharmacologic
promise in animal models to warrant evaluation in man. These studies should focus on those
physicochemical  properties  of  the  new  compound  that  could  affect  drug  performance  and
development of an efficacious dosage form. A thorough understanding of these properties may
ultimately  provide  a  rationale  for  formulation  design,  or  support  the  need  for  molecular
modification.
Objective: The overall objective of preformulation testing is to generate information useful
to the formulation in developing stable and bioavailable dosage forms.
Scope:  The  use  of  preformulation  parameters  maximizes  the  chances  in  formulating  an
acceptable, safe, efficacious and stable product.
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10.1.4.1 Angle of repose45:
The angle of repose is the maximum angle that the plane of powder makes with the horizontal
surface on rotation. Angle of repose is helpful in assessment of flow properties of particles which
could be further related to packing densities and mechanical arrangements of particles.
The angle of repose of granules  was determined by the fixed funnel  and free standing cone
method. The accurately weighed granules were taken in a funnel. The height of the funnel was
adjusted in such a manner that the tip of the funnel just touched the apex of the heap of the
granules.  The granules were allowed to flow through the funnel freely onto the surface.  The
diameter of the powder cone measured and angle of repose was calculated using the following
equation.
Tan θ = h/r  
                                              
                                          Where h = height of the powder heap
                                                     r = radius of the powder heap
                                                     θ = is the angle of repose.
Table 10.1.4.1 Significance of Angle of Repose
S. No. Angle of
repose
Flow
property
1 <25 Excellent
2 25-30 Good
3 30-40 Passable
4 >40 Poor
10.1.4.2 Determination of Bulk Density and Tapped Density45:
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Bulk Density Determination: 
      Bulk density of a compound varies substantially with the method of crystallization, milling or
formulation.  It  is  of great  importance when one considers  the size of a high – dose capsule
product or the homogeneity of a low dose formulation in which there are large differences in
drug and excipient densities. In addition to bulk density, it is frequently desirable to know the
true density of a powder for computation of void volume or porosity of packed powder beds.
      Weighed quantity of the powder (W) was taken in a graduated measuring cylinder and 
volume (V0) was measured and bulk density was calculated using formula,
Bulk density = weight of powder/ volume of powder
B.D = W/V0 g/ml
Tapped Density Determination:
       Weighed of powder was taken in a graduated cylinder and the volume was measured (V0).
The graduated cylinder was fixed in the tapped densitometer and tapped for 500,750 and 1250
times until the difference in the volume after consecutive tapping was less than 2%.the final reading
was denoted by (Vf) the volume of blend was used to calculate the tapped density, hausner’s ratio and
Carr’s index.
Tapped density =W/Vf g/ml
Where W = Weight of the powder
V0 = Initial volume
Vf = final volume 
10.1.4.3 Carr’s Compressibility Index45:
An indirect method of measuring powder flow from bulk densities was developed by Carr. The
percentage compressibility of a powder was a direct measure of the potential powder arch or
bridge  strength  and  stability.  Carr’s  index  of  each  formulation  was  calculated  according  to
equation given below:  
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Carr’s Compressibility Index (%)   =      [(TD-BD) X 100] / TD
            Where, TD = Tapped density and BD = bulk density
        Table no 10.1.4.3 Relationships between % Compressibility and Flowability:
Sr. No. % Compressibility Flowability
1 5 – 15 Excellent
2 12 – 16 Good
3 18 – 21 Fair  to Passable
4 23 – 35 Poor
5 33 – 38 Very Poor
6 > 40 Extremely Poor
10.1.4.4 Hausner’s Ratio45:
Hausner’s  Ratio indicates the flow properties  of the powder and is measured by the ratio of
tapped density to bulk density
.
 It is the ratio of tapped density and bulk density. Hausner found that
this  ratio  was related to inter  particle  friction and,  as  such,  could be used to  predict  powder  flow
properties. Generally a value less than 1.25 indicates good flow properties, which is equivalent to 20% of
Carr’s index.
Hausner’s Ratio     =    Tapped density/Bulk Density
Table no 10.1.4.4 Significance of Hausner’s ratio
Sr.
No.
Hausner’s
Ratio
Property
1 0- 1.2 Free flowing
2 1.2- 1.6 Cohesive
powder
10.1.5 Formulation development:  
10.1.5.1 Formulation design for Dry Granulation:
1. Trial 1 (F1)
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Aim:  To  take  a  trial  batch  of  combination  of  Tenofovir  DF  &Lamivudine  by  dry
granulation method
Formula
                       Table no 10.1.5.1.1 Working Formula F1
Sr.
No.
Ingredients Grade Rational 
use
Quantity      
( mg/tab).
1 Tenofovir DF IH API 300
2 Lamivudine USP API 300
3
Microcrystaline cellulose (Avicel 
PH101)
USP Diluent 50
4 Croscarmellose Sodium USP Disintegrant 30
5 Magnesium Stearate USP Lubricant 10
Extragranular Materials
6 Microcrystaline cellulose (Avicel 
PH102)
USP Diluent 44
7 Croscarmellose Sodium USP Disintegrant 20
Lubrication
8 Magnesium Stearate USP Lubricant 6.0
10.1.5.1 Steps involved in the Trial (F1) by Dry Granulation Method:
1) Dispensing: Carryout the dispensing of the active pharmaceutical ingredient and excipients.
2) Sifting:  Sift  Tenofovir  DF  through  sieve  no  #20  and  Lamivudine  through  no  #40.  Sift
Microcrystalline  Cellulose  (Avicel  PH101),  Croscarmellose  sodium (Primellose),  through
#40 sieve and Magnesium Stearate through no #60 sieve.
3) Drymixing:  Mix  the  sifted  material  Tenofovir  DF,  Lamivudine,  Avicel  PH  101  and
Croscarmellose Sodium for 10 minute in a blender. Add the sifted Magnesium Stearate to the
above blend and mix for 5 minutes.
4) Compaction: Pass the above blend through roller compactor and collect the flakes.
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5) Milling : Mill the flakes  using multimil with 2.0 mm screen and sift through sieve no #20
and the retain again milled through 1.5 mm screen and retains pass through sieve no #20. 
6) Sifting  of  Extra  Granular  and  Lubricating  Material:  Sift  Microcrystalline  cellulose
(Avicel PH 102) and Croscarmellose sodium through sieve no #40 
7) Prelubrication:  Sift the dried granules to the Octagonal Blender, add the microcrystalline
cellulose (Avicel PH 102) and Croscarmellose sodium which are pass through sieve no. #40,
and rotate the blender for 10 min at 15 rpm.
8) Lubrication: Weigh the Magnesium Stearate, pass it through sieve no. #60. Add this to the
above prelubricated material and blend for 5 min at 15 rpm.
9) Compression:  Compress  the  lubricated  blend  on  D/B tooling  compression  machine  by
using 18´ 8 mm Standard Concave punch plain surface on both sides.
Coating Solution Preparation: 
Film coating solution Preparation:
  Add the Opadry-White to purified water under constant stirring with mechanical stirrer for 45
minutes                                                                                                                                               
Coating:  Load  the  core  tablets  into  the  coating  pan  and  coat  the  tablets  with  film coating
solution.                                                                                                                          
Coating parameter:                                                                
• % Of solid content: 10%
• % Of build up: 3%
• Equipment name: Pharma R&D cota
• Pan Speed: 15 to 20 rpm
• Inlet temperatures: 60 °C
2. Trial 2 (F2)
 Aim: To take a trial batch similar to F1 in with  increasing  concentration of CCS .
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3. Trial 3 (F3)
Aim: To take a trial batch in which the two API’s are separately compacted, milled
blended, mixed and compressed 
Formula
                       Table no 10.1.5.1.2 Working Formula F3
Sr.
No.
Ingredients Grade Rational use Quantity
(mg/tab)
1 Tenofovir DF IH API 300
2 Microcrystaline  cellulose  (Avicel
PH101)
USP Diluent 30
3 Croscarmellose Sodium USP Disintegrant 13
4 Magnesium Stearate USP Lubricant 5
5 Lamivudine USP API 300
6 Microcrystaline  cellulose  (Avicel
PH101)
USP Diluent 225
7 Sodium Starch Glycolate (Type A) USP Disintegrant 28
8 Magnesium Stearate USP Lubricant 3.0
 Steps involved in the Trial 3 (F3) by Dry Granulation Method:
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1.Dispensing : Carryout the dispensing of the active pharmaceutical ingredient and excipients in
dispensing booth.
2.Sifting  :  Sift  Tenofovir  DF  through  sieve  no  #20  and  Lamivudine  through  no  #40.  Sift
Microcrystalline Cellulose (Avicel PH101), Sodium Starch Glycolate (Type A), Croscarmellose
sodium (Primellose), through #40 sieve and Magnesium Stearate through no #60 sieve.
3.Drymixing  :  Mix  the  sifted  material  Tenofovir  DF,  Avicel  PH  101  and  Croscarmellose
Sodium for 10 minute in a blender. Add the sifted Magnesium Stearate to the above blend and
mix for  5  minutes.  Mix the  sifted  material  Lamivudine,  Avicel  PH 101 and Sodium Starch
Glycolate for 10 minute in a blender. Add the sifted Magnesium Stearate to the above blend and
mix for 5 minutes.
4.Compaction : Pass the above blend of Tenofovir DF through roller compactor and collect the
flakes. Then pass the blend of Lamivudine through the roller compactor and collect the flakes.
5.Milling : Mill the flakes  using multimil with 2.0 mm screen and sift through sieve no #20 and
the retains again mill through 1.5 mm screen and retains pass through sieve no #20. 
6. Mixing : Mix the granules of Tenofovir DF and Lamivudine for 5 miuntes.
7.Compression : Compress the lubricated blend on D/B tooling compression machine by using
13.5 mm  round Standard Concave  punch  plain surface on both sides.
Coating Solution Preparation: 
Film coating solution Preparation: Similar to trial F1
4. Trial 4 (F4)
Aim:  To  take  a  trial  batch  similar  to  F3  by  adding  MCC  Avicel  PH  102  and
Magnesium Stearate as extra granular portion. 
10.1.5.2 Formulation design for Wet Granulation:
       DEPT. of Pharmaceutics, R.V.S College of Pharmaceutical Sciences   Page 
                                                             Experimental work
5. Trial 5 (F5)
Aim: To take a trial batch by wet granulation method. 
Formula
                       Table no9.1.5.2 Working Formula F5
Sr.
No.
Ingredients Grade Rational use Quantity
(mg/tab)
1 Tenofovir DF IH API 300
2 Microcrystaline  cellulose  (Avicel
PH101)
USP Diluent 100
3 Croscarmellose Sodium USP Disintegrant 28
4 Purified Water USP Binder
solution
q.s
5 Lamivudine USP API 300
6 Microcrystaline  cellulose  (Avicel
PH101)
USP Diluent 140
7 Sodium Starch Glycolate (Type A) USP Disintegrant 12
8 Purified Water Binder
solution
q.s
Extra granular materials
9 Microcrystaline  cellulose  (Avicel
PH101)
USP Diluent 98
10 Croscarmellose Sodium USP Disintegrant 12
Lubrication
11 Magnesium Stearate USP Lubricant 10
Steps involved in the Trial 5 (F3) by Wet Granulation Method:
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1.Dispensing: Carryout the dispensing of the active pharmaceutical ingredient and excipients in
dispensing booth.
2.Sifting:  Sift  Tenofovir  DF  through  sieve  no  #20  and  Lamivudine  through  no  #40.  Sift
Microcrystalline Cellulose (Avicel PH101), Sodium Starch Glycolate (Type A), Croscarmellose
sodium (Primellose), through #40 sieve and Magnesium Stearate through no #60 sieve.
3.Drymixing of Tenofovir DF:  Mix the sifted material Tenofovir DF, MCC (Avicel) PH 101
and Croscarmellose Sodium for 10 minute in rapid mixing granulator.
4. Granulation: Granulate the blend using purified water as the binder soluton.
5. Drying: Dried the wet granules using fluidized bed dryer. Check the LOD of the granules.
6.Drymixing of Lamivudine:  Mix the sifted material Lamivudine, MCC (Avicel) PH 101 and
Sodium Starch Glycolate for 10 minute in rapid mixing granulator.
7. Granulation: Granulate the blend using purified water as the binder solution.
8. Drying: Dried the wet granules using fluidized bed dryer. Check the LOD of the granules.
9. Sifting  of  Extra  Granular  and  Lubricating  Material:  Sift  Microcrystalline  cellulose
(Avicel PH 102) and Croscarmellose sodium through sieve no #40 
10.Prelubrication:  Sift the dried granules to the Octagonal Blender, add the microcrystalline
cellulose (Avicel PH 102) and Croscarmellose sodium which are pass through sieve no. #40, and
rotate the blender for 10 min,
11.Lubrication: Weigh the Magnesium Stearate, pass it through sieve no. #60. Add this to the
above prelubricated material and blend for 5 min.
6.Compression: Compress the lubricated blend on D/B tooling compression machine by using
19.4 ´  9mm Capsule shaped punch plain on both sides.
Coating Solution Preparation: 
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Film coating solution Preparation: Similar to trial F1
6. Trial 6 (F6)
Aim: To take a trial batch similar to trial 5 (F5) with increased concentration of CCS
and addition of Pregelatinized Starch and Lactose Monohydrate.
10.1.5.3 Formulation design for Bilayer Tablets by Wet Granulation:
7. Trial 7 (F7)
Aim: To take a trial batch by compressing the API’s as bilayer tablets 
Formula
                       Table no 10.1.5.3 Working Formula F7
Sr. 
No
Ingredients Grade Rational use Quantity 
(mg/tab)
Layer 1 
1 Tenofovir DF IH API 300
2 Lactose Monohydrate (Pharmatose 
200M)
USP Diluent 150
3 Microcrystaline cellulose (Avicel 
PH101)
USP Diluent 73
4 Croscarmellose Sodium USP Disintegrant 13
5 Pregelatinized Starch USP Binder 33
6 Purified Water USP Binder 
solution
q.s
Extra granular materials
7 Microcrystaline cellulose (Avicel 
PH101)
USP Diluent 73
8 Croscarmellose Sodium USP Disintegrant 13
Lubrication
9 Magnesium Stearate USP Lubricant 7
Layer 2
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10 Lamivudine USP API 300
11 Microcrystaline cellulose (Avicel 
PH101)
USP Diluent 150
12 Sodium Starch Glycolate (Type A) USP Disintegrant 9
13 Purified Water USP Binder 
solution
q.s
Extra granular materials
14 Microcrystalline cellulose (Avicel 
PH101)
USP Diluent 80
15 Sodium Starch Glycolate (Type A) USP Disintegrant 9
Lubrication
16 Magnesium Stearate USP Lubricant 7
Steps involved in the Trial 7 (F7) by Wet Granulation Method:
1.Dispensing: Carryout the dispensing of the active pharmaceutical ingredient and excipients.
2.Sifting:  Sift  Tenofovir  DF  through  sieve  no  #20  and  Lamivudine  through  no  #40.  Sift
Microcrystalline Cellulose (Avicel PH101), Sodium Starch Glycolate (Type A), Croscarmellose
sodium (Primellose), through #40 sieve and Magnesium Stearate through no #60 sieve.
Layer 1
3.Drymixing of Tenofovir DF:  Mix the sifted material Tenofovir DF, MCC (Avicel) PH 101
and Croscarmellose Sodium for 10 minute in rapid mixing granulator.
4. Granulation: Granulate the blend using purified water as the binder solution.
5. Drying: Dried the wet granules using fluidized bed dryer. Check the LOD of the granules.
6. Sifting  of  Extra  Granular  and  Lubricating  Material:  Sift  Microcrystalline  cellulose
(Avicel PH 102) and Croscarmellose sodium through sieve no #40 
7.Prelubrication:  Sift  the dried granules  to  the Octagonal  Blender,  add the microcrystalline
cellulose (Avicel PH 102) and Croscarmellose sodium which are pass through sieve no. #40, and
rotate the blender for 10 min,
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8.Lubrication:  Weigh the Magnesium Stearate, pass it through sieve no. #60. Add this to the
above prelubricated material and blend for 5 min.
Layer 2
 9.Drymixing of Lamivudine: Mix the sifted material Lamivudine, MCC (Avicel) PH 101 and
Sodium Starch Glycolate for 10 minute in rapid mixing granulator.
10. Granulation: Granulate the blend using purified water as the binder solution.
11. Drying: Dried the wet granules using fluidized bed dryer. Check the LOD of the granules.
12. Sifting  of  Extra  Granular  and  Lubricating  Material:  Sift  Microcrystalline  cellulose
(Avicel PH 102) and Croscarmellose sodium through sieve no #40 
13.Prelubrication:  Sift the dried granules to the Octagonal Blender, add the microcrystalline
cellulose (Avicel PH 102) and Croscarmellose sodium which are pass through sieve no. #40, and
rotate the blender for 10 min,
14.Lubrication: Weigh the Magnesium Stearate, pass it through sieve no. #60. Add this to the
above prelubricated material and blend for 5 min.
15.Compression: Compress the lubricated blend on D/B tooling compression machine by using
19.8 ´  10.2mm Capsule shaped punch embossing “I” surface on one side and “49” on other side.
Coating Solution Preparation: 
Film coating solution Preparation: Similar to trial F1
8. Trial 8 (F8)
Aim:  To  take  a  trial  batch  similar  to  Trial  F7  with  increased  concentration  of
superdisintegrants
9. Trial 9 (F9)
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Aim: To take  a  trial  batch similar  to  Trial  F8  with  increased  concentration  of
superdisintegrants.
10. Trial 10 (F10)
Aim: To take a trial batch similar to Trial  F9 in which the size of Tenofovir DF
reduced by micronization process. 
11. Trial 11 (F11)
Aim:  To  take  a  trial  batch  similar  to  Trial  F10  in  which  the  concentration  of
Microcrystalline  cellulose  (Avicel  PH 101)  is  increased  and  the  concentration  of
Pharmatose was reduced in Tenofovir DF part.  
12. Trial 12 (F12)
Aim: To take a trial batch similar to Trial F10 by increasing the concentration of CCS
and include the Pregelatinized Starch in the extragranular part of Tenofovir DF layer. 
10.2 Formulation design:
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Table no: 10.2.1 Formulation design for Dry Granulation
Table no: 10.2.2 Formulation design for Wet Granulation:
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S.N Ingredients
F1 F2 F3 F4
1 Tenofovir DF 300 300 300 300
2 Lamivudine 300 300 300 300
3 MCC(Avicel PH101 of 
layer 1)
50 25 30 145
4 MCC(Avicel PH101 of 
layer 2)
- - 225 30
5 CCS 30 55 13 13
6 SSG type-A - - 28 28
7 Magnesium  Stearate of 
layer 1
10 10 5 5
8 Magnesium Stearate of 
layer 2
- - 3 3
Extragranular materials
9 Avicel PH102 44 20 - 73
10 CCS 20 45 - -
11 Magnesium Stearate 10 5 - 3
12 Total wt 760 760 904 900
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All above values are taken in mg
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S.N Ingredients F5 F6 F7 F8 F9 F10 F11 F12
Tenofovir DF Layer 
1 Tenofovir DF 300 300 300 300 300 300 300 300
2 Pharmatose 200m - 151 153 153 153 153 60 142
3 MCC
 (Avicel PH101)
100 66 73 66 60 60 153 60
4 CCS 28 28 13 20 26 26 26 30
5 Starch 1500 - 33 33 33 33 33 33 -
Extragranular part
6 MCC
(Avicel PH102)
- 73 66 60 60 60 75
7 CCS - 13 20 26 26 26 30
8 Starch 1500 - - - - - - - 15
Lubrication
9 Magnesium 
Stearate
- - 7 7 7 7 7 7
Lamivudine  Layer
1 Lamivudine 300 300 300 300 300 300 300 300
2 MCC
(Avicel PH101)
140 150 155 150 145 145 145 145
3 SSG type-A 12 14 9 14 20 20 20 20
Extragranular Part
4   MCC
(AvicelPH102)
- - 80 75 68 68 68 68
5 SSG type-A - - 9 14 20 20 20 20
Lubrication
6 Magnesium 
Stearate
- - 7 7 7 7 7 -
Extragranular Part of Layer 1+Layer 2
7 MCC
(Avicel PH102)
98 130 - - - - - -
8 CCS 12 20 - - - - - -
9 SSG - 14 - - - - - -
Lubrication  of Layer 1+Layer 2
10 Magnesium. 
Stearate
10 15 - - - - - -
11 Total wt 1000 1220 1225 1224 1225 1225 1225 1225
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10.3.1 Physical parameters of the uncoated tablet of optimized formula:
 Tablet weight         : 1225 mg ± 3%
 Thickness              : 7.10mm ± 0.10 mm
 Hardness         :15 to 20 Kp
 Friability                : Not more than 1% 
 Disintegration time : Not more than 15 min
10.3.2 Physical parameters of the coated tablet of optimized formula:
 Tablet weight          : 1265 mg ± 5%
 Thickness                : 7.40mm ± 0.10 mm
 Disintegration time  : Not more than 15 min
10.4 EVALUATION OF TABLETS6:-
10.4.1 Hardness test:
     Tablet  requires  a  certain  amount  of  strength or  hardness  and  resistance  to  friability  to
withstand mechanical shock of handling in manufacture, packing and shipping.  Hardness tester
measured the hardness of tablet. Five tablets from each batch were used for hardness studies and
results were expressed in Kilo Pascals.
10.4.2 Thickness and diameter:
The thickness and diameter of tablets was carried out using verniercaliper. Five tablets were used
for the above test from each batch results were expressed in millimeter.
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10.4.3 Weight variation test:
Twenty tablets were selected at random, individually weighed in a single pan electronic balance
and the average weight was calculated. The uniformity of weight was calculated. The uniformity
of weight was determined according to I.P. specification. As per U.S.P not more than two of
individual weight should deviate from average weight by more than 5% and none deviate more
than twice that percentage.
10.4.4 Friability test:
 It  was done in Roche friabilator apparatus where the tablets were subjected to the combined
effect of abrasion and shock by utilizing a plastic chamber that revolve at 25 rpm dropping the
tablets at a distance of six inches with each revolution. Preweighed samples of 20 tablets were
placed in the friabilator, which is then operated for 100 revolutions. The tablets were then dusted
and reweighed. Conventional compressed tablets that loss less than 0.5 to 1.0% of their weight
are generally considered acceptable.                  
                          % F = {1-(Wt/W)} ×100
                          where % F = Friability in percentage
                                       W = Initial weight of tablets
                                      Wt = Weight of tablets after revolution
10.5 TENTATIVE METHOD FOR ASSAY (UV METHOD) 11:
Sample preparation of Tenofovir DF:
Weigh  and  finely  powder  not  less  than  20  tablets.  Transfer  an  accurately  weighed  powder
equivalent to about 100 mg of Tenofovir DF to a 100ml volumetric flask, add 30ml 0.1N HCl
and shake for about 10 min. Make volume up to the mark with 0.1N HCl. Filter the solution with
0.45µm Whatman filter paper. Discard first 3 to 4ml of filtrate and pipette out 1ml of this filtrate
to a 100 ml of volumetric flask and dilute up to the mark with diluents.
Standard preparation of Tenofovir DF: 
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Weigh accurately 100 mg of Tenofovir DF and transfer in to a 100ml volumetric flask, add 20 ml
of   and Shake for about 5 min. Add diluents and shake mechanically for 60 min. Make volume
up to the mark with diluents(0.1N HCl).
Procedure:
Take the absorbance at 260 nm using 0.1N HCl as a blank for a background correction. Take
absorbance in a triplicate of a standard solution and duplicate of a sample preparation.
Sample preparation of Lamivudine:
Weigh  and  finely  powder  not  less  than  20  tablets.  Transfer  an  accurately  weighed  powder
equivalent to about 100 mg of Lamivudine to a 100ml volumetric flask, add 30ml 0.1N HCl  and
shake for about 10 min. make volume up to the mark with 0.1N HCl. Filter the solution with
0.45µm Whatman filter paper. Discard first 3 to 4ml of filtrate and pipette out 1ml of this filtrate
to a 100 ml of volumetric flask and dilute up to the mark with diluents.
Standard preparation of Lamivudine: 
Weigh accurately 100 mg of Lamivudine and transfer in to a 100ml volumetric flask, add 20 ml
of 0.1N HCl  and Shake for about 5 min. add diluents and shake mechanically for 60 min. make
volume up to the mark with diluents(0.1N HCl).
Procedure:
Take the absorbance at 270 nm using 0.1N HCl as a blank for a background correction. Take
absorbance in a triplicate of a standard solution and duplicate of a sample preparation.
10.6 Dissolution studies (UV METHOD) 20
In vitro dissolution studies of Tenofovir DF:
The  release  rate  of  Tenofovir  DF  from  tablets  was  determined.  The  dissolution  test  was
performed using United States Pharmacopoeia (USP) type II (paddle) apparatus,1000 ml of 0.1
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N HCl  at 37 ± 0.5°C and 50 rpm. A sample (10 ml) of the solution was withdrawn from the
dissolution apparatus at the appropriate time for 5 min, and the samples were replaced with fresh
dissolution medium. The samples  were  diluted into a  suitable concentration with water  with
0.1  N  HCl.  Absorbance  of  these  solutions  was  measured  at  260  nm  using  a Shimadzu
UV/Visible double-beam spectrophotometer. Percentage drug release was calculated.
The drug content was calculated using the equation generated from standard calibration curve.
The % drug release was calculated. 
In vitro dissolution studies of Lamivudine:
The release rate of Lamivudine from tablets was determined. The dissolution test was performed
using United States Pharmacopoeia (USP) type II (paddle) apparatus,1000 ml of 0.1 N HCl  at 37
± 0.5°C and 50 rpm. A sample (10 ml) of the solution was withdrawn from the dissolution
apparatus at the appropriate time for 5 min, and the samples were replaced with fresh dissolution
medium. The samples were diluted into a suitable concentration with water with 0.1 N HCl.
Absorbance of these solutions was measured at 270 nm using a Shimadzu UV/Visible double-
beam spectrophotometer. Percentage drug release was calculated.
The drug content was calculated using the equation generated from standard calibration curve.
The % drug release was calculated.
Details of dissolution test: 
• Dissolution test apparatus :  USP II (Paddle)
• Speed :  50 rpm
• Volume of medium :  1000 ml                                                          
• Time interval                                 :  5,10, 15, 20 , 30, 45, and 60
• Medium used : 0.1N HCl
• Temperature :  37 ± 0.5 0C
10.7 Data analysis:
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To analyze  the  mechanism of  release and release  rate  kinetics of  the dosage  form,  the data
obtained were fitted into Zero order, First order, Higuchi matrix, Peppas and Hixson Crowell
model using PSP-DISSO – V2 software. Based on the r-value, the best-fit model was selected.
Zero order kinetics:
Drug dissolution from pharmaceutical dosage forms that do not disaggregate and release the drug
slowly, assuming that the area does not change and No equilibrium conditions are obtained can
be represented by the following equation,
Q t = Q o + K o t
Where Q t  = amount of drug dissolved in time t.
Q o = initial amount of the drug in the solution and
K o = zero order release constant.
First order kinetics:
To study the first order release rate kinetics, the release rate data were fitted to the following
equation,
Log Qt = log Qo + K1t/2.303
Where Qt is the amount of drug released in time t, Qo is the initial amount of drug in the solution
and K1 is the first order release constant.
Higuchi model:
Higuchi  developed several  theoretical  models  to  study the  release  of  water  soluble  and low
soluble drugs incorporated in semisolids and/or solid matrices. Mathematical expressions were
obtained for drug particles dispersed in a uniform matrix behaving as the diffusion media. And
the equation is,
                    Qt = KH ·t1/2
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Where
                   Qt = amount of drug released in time t,
                  KH = Higuchi dissolution constant.
Krosmeyer and Peppas release model:
To study this model the release rate data are fitted to the following equation,
                  Mt / M ¥  = K · t n
Where Mt / M ¥   is the fraction of drug release, K is the release constant, t is the release time and
n is the diffusion coefficient for the drug release that is dependent on the shape of the matrix
dosage form
10.8 SIMILARITY FACTOR AND DISSIMILARITY FACTOR CALCULATION:
The similarity factor (f2) was defined by CDER, FDA, and EMEA as the “logarithmic reciprocal
square root transformation of one plus the mean squared difference in percent dissolved between
the test and reference release profiles”.
              Dissimilarity or difference factor (f1) describes the relative error  between two
dissolution profiles. It approximates the percent error between the curves. The percentage error is
zero when the test and reference release profiles are identical and increases proportionally with
dissimilarity between the two profiles. 
              There are several methods for dissolution profile comparison. f2 is the simplest among
all those methods. Moore & Flanner proposed a model independent mathematical approach to
compare the dissolution profile using two factors f1& f2. 
f1 = { [ å
 t=1 
n½Rt – Tt ½ ] / [ å  t=1 n Rt ] } . 100
f2 = 50. log { [1 + ( 1/n) å
 t=1 
n
 (Rt - Tt ) 2 ] –0.5 . 100}
             Where ‘Rt ’and ‘Tt ’ are the cumulative % dissolved at each of the selected ‘n’ time point
of  the  reference  &  test  product  respectively.  The  factor  f1  is  proportional  to  the  average
difference between the two profiles, where as factor f2 is inversely proportional to the average
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squared difference between the two profiles, with emphasis on the larger difference among all
the time points. The similarity factor f2 and its significance are shown in the following table.
Table 10.8.1 Similarity factor f2 and its significance
S. No. Similarity factor (f2) Significance
1. <50 Test and reference profiles are dissimilar.
2. 50 -100 Test and reference profiles are similar.
3. 100 Test and reference profiles are identical.
4. >100 The equation yields a negative value.
10.9 STABILITY STUDY OF BI-LAYER TABLET32-33
The bi-layer  tablets  were  stored  at  40ºC ± 5ºC and  75% ± 5% relative  humidity  in
stability chamber Samples were withdrawn at  1 month time intervals and evaluated for drug
content, in-vitro drug release study, weight variation, hardness, thickness and friability.
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11.1 PREFORMULATION STUDY
11.1.1 PREFORMULATION STUDIES OF TENOFOVIR DF: 
 API Charcterization-
Tenofovir DF was analyzed for various physical and analytical characterizations and was
found to comply with the in house certificate of analysis of Hetero labs.    
Physical Characterization of Tenofovir DF:
The results of physical characterization of the drug candidate are as follows-
1. Description
            The received sample of Tenofovir DF was found to show the following characteristics
and these are acceptable according to specification.
a) Color: White to off white.
b) Nature: Crystalline powder.
       c) Hygroscopic: slightly hygroscopic
      2. Solubility
            The solubility of the Tenofovir DF was examined in various solvents. The results thus
obtained were as follows-
Table No. 11.1.1.1 Solubility of drug sample
Sr.no Solvent Solubility
1 Water Soluble
2 Acetone Slightly soluble
3 Methanol Sparingly soluble
4 Ethanol Sparingly soluble
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Table No. 11.1.1.2  Other Test Performed
Sr.no Test Specification
Result
1 Loss on Drying(at 750C ) Not more than 1.0%w/w 0.78% w/w
2 Assay: Not less than 97.0% 
w/w and Not more than 
101% w/w
99.5% w/w
3 Density 
i) Bulk
ii) Tapped
0.412 g/ml
0.636g/ml
4 Compressibility Index 35.22%
5 Hausner Ratio 1.543
6 Angle of Repose 32
7 Particle Size # Not less than 98.0% 
should pass through #22
mesh
100 % passed through #22 
mesh
Result: From above result of tests performed the all values are within the limits, it was
concluded  that  the  received  sample  of  Tenofovir  DF  was  pure  and  might  be  used  in  the
formulation.
11.1.2 PREFORMULATION STUDIES of LAMIVUDINE: 
 API Charcterization-
Lamivudine was analyzed for various physical and analytical characterizations and was
found to comply with the in house certificate of analysis of Hetero labs.    
Physical Characterization of Lamivudine:
The results of physical characterization of the drug candidate are as follows-
1. Description
            The received sample of Lamivudine was found to show the following characteristics and
these are acceptable according to specification.
     a) Color: White to off white.
     b) Nature: Crystalline powder.
                                                         
DEPT. of Pharmaceutics, R.V.S College of Pharmaceutical Sciences   Page 79
                                                                 Results and discussion
      2. Solubility
            The solubility of the Tenofovir DFwas examined in various solvents.The results thus
obtained were as follows-
Table No. 11.1.2.1 Solubility of drug sample
Sr.no Solvent Solubility
1 Water Soluble
2 Acetone Slightly soluble
3 Methanol Sparingly soluble
4 Ethanol Sparingly soluble
Table No. 11.1.2.2 Other Test Performed
Sr.no Test Specification
Result
1 Loss on Drying(at 1050C ) Not more than 1.5%w/w 1.2% w/w
2 Assay: Not less than 98.0% 
w/w and Not more than 
101% w/w
99.7% w/w
3 Density 
iii) Bulk
iv) Tapped
0.472 g/ml
0.810 g/ml
4 Compressibility Index 41.78%
5 Hausner Ratio 1.716
6 Angle of Repose 26
7 Particle Size # Not less than 98.0% 
should pass through #22
mesh
100 % passed through #22 
mesh
Result:  From  above  result  of  tests  performed  the  all  values  are  within  the  limits,  it  was
concluded  that  the  received  sample  of  Lamivudine  was  pure  and  might  be  used  in  the
formulation
11.1.3 Identification of Drug
Determination of λ max of Tenofovir DF:
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On the basis of preliminary identification test it was concluded that the drug complied the
preliminary identification. From the scanning of drug, it was concluded that the drug had 
λmax of 259 nm, which was equal to 259 nm as reported. Also, an IR spectrum was 
concordant with the reference spectrum of Tenofovir DF.                                                    
Fig. 11.1.3.1 UV Spectra of Tenofovir DF
Determination of λ max of Lamivudine:
On the basis of preliminary identification test it was concluded that the drug complied the
preliminary identification. From the scanning of drug, it was concluded that the drug had 
λmax of 270 nm, which was equal to 270 nm as reported. Also, an IR spectrum was 
concordant with the reference spectrum of Lamivudine.  
                                                         
DEPT. of Pharmaceutics, R.V.S College of Pharmaceutical Sciences   Page 81
                                                                 Results and discussion
Fig. 11.1.3.2 UV Spectra of Lamivudine
Determination of IR spectrum of Tenofovir DF:
Fig. 11.1.3.3. IR SPECTRA OF TENOFOVIR DF
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From  the  scanning  of  drug,  it  was  concluded  that  the  drug  had,  an  IR  spectrum  that  was
concordant with the reference spectrum of Tenofovir  DF
      Solubility: Tenofovir DF is freely soluble in water
                                 Determination of IR spectrum of Lamivudine
Fig. 11.1.3.4.  IR SPECTRA OF LAMIVUDINE
From the scanning of drug, it was concluded that the drug had, an IR spectrum that was concordant
with the reference spectrum of Lamivudine.
      Solubility: Lamivudine is freely soluble in water.
Determination of IR spectrum of Tenofovir DF +Lamivudine:
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Fig.11.1.3.5. IR SPECTRA OF TENOFOVIR DF +LAMIVUDINE
 11.2 DRUG EXCIPIENTS COMPATABILITY STUDIES
Results of drug excipient compatibility studies: 
Drug-Excipient compatibility studies form an important part of preformulation studies for
the determination of interaction between drug and excipient. It is determined after storage of
specific time period by using suitable analytical techniques and the results are indicating that
there is no interaction between drug and excipients.
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Fig. 11.2.I IR SPECTRA OF TENOFOVIR DF +LAMIVUDINE + LACTOSE
MONOHYDRATE (PHARMATOSE 200M)
Fig.11.2.II IR SPECTRA OF TENOFOVIR DF +LAMIVUDINE +MCC (AVICEL PH 101)
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Fig.11.2.III IR SPECTRA OF TENOFOVIR DF +LAMIVUDINE +MCC (AVICEL PH 102) 
Fig. 11.2.IV IR SPECTRA OF TENOFOVIR DF +LAMIVUDINE +CCS
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Fig.11.2.V IR SPECTRA OF TENOFOVIR DF +LAMIVUDINE +SSG
Fig. 11.2.VI IR SPECTRA OF TENOFOVIR DF +LAMIVUDINE + PREGELATINIZED
STARCH (STARCH 1500)
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Fig.11.2.VII IR SPECTRA OF TENOFOVIR DF +LAMIVUDINE +MAGNESIUM
STEARATE
Fig. 11.2.VIII IR SPECTRA OF TENOFOVIR DF +LAMIVUDINE +OPADRY WHITE
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      Fig.11.2.IX IR SPECTRA OF TENOFOVIR DF+ PLACEBO
Fig. 11.2.X IR SPECTRA OF LAMIVUDINE + PLACEBO
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Fig.11.2.XI IR SPECTRA OF TENOFOVIR DF +LAMIVUDINE + PLACEBO 
Fig.11.2.XII IR SPECTRA OF PLACEBO
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TABLE NO.11.2.1 Drug-exicipient compatibility Result:
Sr. 
No Name of the Excipient
Ratio
API: 
Expt
Initial 
Observation
Final observation
Conclusion
   40°C/75% RH
2nd week 4th week
1 Tenofovir DF - White to off  
white
White to 
off  white
White to 
off  white Compatible
2 Lamivudine White to off  
white
White to 
off  white
White to 
off  white Compatible
3 Tenofovir DF +Lamivudine - White to off  
white
White to 
off  white
White to 
off  white Compatible
4
Tenofovir DF +Lactose 
monohydrate(Pharmatose 
200m) 1:2
White fine 
powder
White 
fine 
powder
White 
fine 
powder
Compatible
5
Tenofovir DF + 
Microcrystalline Cellulose 
(Avicel PH101) 1:2 off-white off-white off-white Compatible
6
Tenofovir DF + 
Microcrystalline Cellulose 
(Avicel PH101) 1:2 off-white off-white off-white Compatible
7
Tenofovir DF + 
Pregelatinized Starch 
(Starch 1500) 1:0.5 off-white off-white off-white Compatible
8
Tenofovir DF+ Sodium 
starch glycolate-A 1:0.5 White White White Compatible
9
Tenofovir DF+ 
Croscarmellose 
sodium(Primellose)
1:0.5 Off white Off white Off white Compatible
10
Tenofovir DF+ Magnesium 
stearate 1:0.05 White White White Compatible
11
Tenofovir DF+ Opadry 
White 1:0.25 White  White  White Compatible
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12
Lamivudine +Lactose 
monohydrate(Pharmatose 
200m) 1:2
White fine 
powder
White 
fine 
powder
White 
fine 
powder
Compatible
13
Lamivudine + 
Microcrystalline Cellulose 
(Avicel PH101) 1:2 off-white off-white off-white Compatible
14
Lamivudine + 
Microcrystalline Cellulose 
(Avicel PH101) 1:2 off-white off-white off-white Compatible
15
Lamivudine + Pregelatinized
Starch (Starch 1500) 1:0.5 off-white off-white off-white Compatible
16
Lamivudine+ Sodium starch 
glycolate-A 1:0.5 White White White Compatible
17
Lamivudine+ 
Croscarmellose 
sodium(Primellose)
1:0.5 Off white Off white Off white Compatible
18
Lamivudine+ Magnesium 
stearate 1:0.05 White White White Compatible
19 Lamivudine+ Opadry White 1:0.25 White  White  White Compatible
20
Tenofovir DF + 
Lamivudine+Lactose 
monohydrate(Pharmatose 
200m)
1:2 White fine powder
White 
fine 
powder
White 
fine 
powder
Compatible
21
Tenofovir DF + 
Lamivudine+ 
Microcrystalline Cellulose 
(Avicel PH101)
1:2 off-white off-white off-white Compatible
22
Tenofovir DF +Lamivudine 
+ Microcrystalline Cellulose
(Avicel PH101) 1:2 off-white off-white off-white Compatible
23
Tenofovir DF + 
Lamivudine+ Pregelatinized 
Starch (Starch 1500) 1:0.5 off-white off-white off-white Compatible
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24
Tenofovir DF + 
Lamivudine+ Sodium starch 
glycolate-A
1:0.5 White White White Compatible
25
Tenofovir DF + 
Lamivudine+ 
Croscarmellose 
sodium(Primellose)
1:0.5 Off white Off white Off white Compatible
26
Tenofovir DF + 
Lamivudine+ Magnesium 
stearate
1:0.05 White White White Compatible
27
Tenofovir DF + 
Lamivudine+ Opadry White 1:0.25 White  White  White Compatible
28 Tenofovir DF+ Placebo 1:2 Off white Off white Off white Compatible
29 Lamivudine+ Placebo 1:2 Off white Off white Off white Compatible
30
Tenofovir DF + 
Lamivudine+ Placebo 1:2 Off white Off white Off white Compatible
It was concluded that there was no interference in the functional group as the principle peaks 
of the Tenofovir DF and Lamivudine were found to be unaltered in the drug-polymer 
physical mixture, indicating they were compatible chemically.  
11.3 PREPARATION OF STANDARD CURVE                                                                   
11.3.1 PREPARATION OF STANDARD CURVE OF TENOFOVIR DF:
From the standard curve of Tenofovir DF was observed that the drug obeys beer’s law in
concentration range of 2-10 µg/ml in0.1N HCl. The linear regression equation generated
was used for the calculation of amount of drug.
Table.11.3.1 Standard curve of Tenofovir DF in 0.1N HCl
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Fig. 11.3.1 Standard curve of Tenofovir DFin 0.1N HCl
11.3.2 PREPARATION OF STANDARD CURVE OF LAMIVUDINE:
From the standard curve of Lamivudine was observed that  the drug obeys beer’s  law in
concentration range of 2-10 µg/ml in0.1N HCl. The linear regression equation generated
was used for the calculation of amount of drug.
Table.11.3.2 Standard curve of Lamivudine in 0.1N HCl
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Sr.
No.
Conc.(µg/ml) Absorbance
1
2 0.051
2
4 0.099
3
6 0.149
4
8 0.202
5
10 0.239
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Fig. 11.3.2 Standard curve of Lamivudine in 0.1N HCl
11.4 PREFORMULATION STUDIES OF GRANULES:
Table No. 11.4.1 Flow properties of blends of different formulations
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Sr.
No.
Conc.(µg/ml) Absorbance
1
2 0.121
2
4 0.223
3
6 0.315
4
8 0.421
5
10 0.515
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BATCH
BULK
DENSITY
(gm/ml)
TAPPED
DENSITY
(gm/ml)
CARR’S
INDEX
(%)
HAUSNER’
S RATIO
RESULT
Tenofovir DF 0.412 0.636 35.29 1.54 Very poor
Lamivudine 0.472 0.810 41.66 1.71 Extremly
poor
F1 0.601 0.860 30.1 1.43 Poor
F2 0.645 0.833 22.58 1.29 Poor
F3 0.560 0.800 30.5 1.46 Poor
F4 0.550 0.790 30.37 1.43 Poor
F5 0.450 0.590 23.70 1.27 Poor
F6 0.420 0.550 23.63 1.30 Poor
F7 _ _ _ _ _
F8 _ _ _ _ _
F9 _ _ _ _ _
F10 _ _ _ _ _
F11 _ _ _ _ _
F12 _ _ _ _ _
Table No. 11.4.2 Flow properties of Tenofovir DF blends of different formulations
BATCH
BULK
DENSITY
(gm/ml)
TAPPED
DENSITY
(gm/ml)
CARR’S
INDEX
(%)
HAUSNER’
S RATIO
RESULT
F1 _ _ _ _ _
F2 _ _ _ _ _
F3 0.650 0.870 25.86 1.33 Poor
F4 0.650 0852 25.46 1.30 Poor
F5 0.465 0.598 22.24 1.28 Poor
F6 0.454 0.580 21.72 1.27 Poor
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F7 0.43 0.56 23.21 1.3 Poor
F8 0.445 0.56 20.54 1.25 Fair
F9 0.44 0.55 20.00 1.25 Fair
F10 0.45 0.55 18.18 1.22 Fair
F11 0.44 0.56 21.43 1.27 Fair
F12 0.45 0.56 19.64 1.24 Fair
Table No. 11.4.3 Flow properties of Lamivudine blends of different formulations
BATCH
BULK
DENSITY
(gm/ml)
TAPPED
DENSITY
(gm/ml)
CARR’S
INDEX
(%)
HAUSNER’
S RATIO
RESULT
F1 _ _ _ _ _
F2 _ _ _ _ _
F3 0.526 0.833 36.85 1.58 poor
F4 0.530 0.833 36.85 1.58 poor
F5 0.447 0.572 21.85 1.27 Fair
F6 0.435 0.571 23.81 1.31 poor
F7 0.432 0.532 18.8 1.23 Fair
F8 0.430 0.530 18.86 1.23 Fair
F9 0.435 0.54 19.44 1.24 Fair
F10 0.430 0.540 20.37 1.25 Fair
F11 0.425 0.535 20.56 1.25 Fair
F12 0.470 0.58 18.96 1.23 Fair
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Result:   Preformulation  study  of  powder  blend  had  shown  that  the  blend  had  passable
parameters  like Angle  of Repose,  Bulk density,  Tapped density,  Carr’s  index and Hausner’s
ratio.
11.5 EVALUATION PARAMETERS OF TABLETS
Table no: 11.5.1 Evaluation parameters of formulations for uncoated
tablets
Formulation
code
Evaluation parameter
Thickness ±
S.D. (mm)
 (n = 5)
Hardness ±
S.D. (KP) 
(n = 5)
Friability
(%)
Average
weight
variation
(n=20)
Drug
content
(Tenofovir
DF)
(%)
Drug 
content
(Lamivudine)
(%)
Disintegration
Time
F1 6.40±0.10 11.00±1.0 0.74 760±5.00 97.18 97.13 10-12 min
F2 6.00±0.10 12.00±1.0 0.9 760±5.00 96.98 97.27 10-12min
F3 6.40±0.10 12.00±1.0 0.35 900±8.00 98.36 97.03 10-12 min
F4 6.40±0.10 10.00±1.0 0.41 900±6.00 97.65 98.63 7-9 min
F5 6.60±0.10 16.00±1.5 0.42 1000±5.00 97.59 98.33 3-4 min
F6 7.10±0.10 15.00±1.0 0.31 1220±5.00 98.41 98.46 3-4 min 
F7 7.10±0.10 15.00±1.0 0.29 1225±5.00 98.52 98.76 2-3 min 
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F8 7.10±0.10 15.00±1.0 0.25 1225±5.00 98.21 98.78 1-2 min
F9 7.10±0.10 15.00±1.0 0.31 1225±5.00 98.90 98.47 1-2 min
F10 7.00±0.10 15.00±1.0 0.28 1225±5.00 98.66 98.36 2-3 min
F11 7.10±0.10 17.00±1.0 0.26 1225±5.00 98.56 98.07 2-3 min
F12 7.00±0.10 17.00±1.5 0.24 1225±5.00 97.36 98.45 2-3 min
Tableno.11.5.2 Evaluation parameters of formulations for film coated tablets
11.6 PHYSICOCHEMICAL EVALUATION:
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Formulation code
Evaluation parameter
Thickness ±
S.D. (mm)
(n = 5)
Hardness ±
S.D. (Kp)
(n = 5)
Average
weight
variation
(n=20)
Disintegration
Time
F1 6.50±0.10 17.0±1.0 780±6.00 10-12 min
F2 6.50±0.10 17.0±1.0 780±6.00 10-12 min
F3 6.50±0.10 15.0±2.0 930±8.00 10-12 min
F4 6.40±0.10 15.0±2.0 930±8.00 8-10 min
F5 6.80±0.10 22.0±2.0 1030±5.00 4-5 min
F6 7.40±0.10 15.0±1.0 1260±5.00 3-5 min
F7 7.40±0.10 25.0±1.0 1265±8.00 2-3 min
F8 7.40±0.10 25.0±1.0 1265±8.00 2-3 min
F9 7.40±0.10 25.0±1.0 1265±8.00 2-3 min
F10 7.25±0.10 22.0±2.0 1265±5.00 2-3 min
F11 7.40±0.10 25.0±2.0 1265±5.00 3-4 min
F12 7.30±0.10 22.0±2.0 1265±5.00 2-3 min
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 The  prepared  tablets  were  subjected  to  preliminary  characterization  such  as  hardness,
thickness, % weight variation, friability and drug content. The evaluated parameters were
within acceptable range for all the   formulations. The values are indicated in below Table.
Table no: 11.6.1 Range for value of preliminary characterization of formulations
Parameters Range
Hardness (kp) 15.0-25.0
Thickness (mm) 6.50-7.40
Weight variation (%) ±5%
% Friability Not more than 1.0%
Assay(%) 96.98-98.90
Result: Evaluation parameters  of formulation,  it  showed that  the all  the parameters  viz.
hardness, thickness, friability, average weight and content uniformity were in the passable
range.
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11.7 RESULTS OF IN-VITRO RELEASE PROFILE
11.7.1 Results of In-Vitro Release Profile of Tenofovir DF:  
Table.11.7.1.1 In-Vitro Release Profile
Sr. No. Time (min) F1 F2 F3 F4 F5 F6
1 5 10.08 15.36 16.32 26.88 36.48 37.44
2 10 18.24 21.12 22.08 34.08 47.04 48.48
3 15 26.88 29.28 31.2 44.64 57.12 56.64
4 20 35.04 37.44 38.4 56.16 65.28 67.68
5 30 42.24 44.16 45.12 63.36 72.96 73.92
6 45 52.32 52.8 52.32 69.6 79.68 83.52
7 60 65.28 66.72 66.24 77.28 85.92 93.12
Table.11.7.1.2 In-Vitro Release Profile
Sr. No. Time
(min)
F7 F8 F9 F10 F11 F12
1 5 61.92 72.48 72.48 72.96 71.04 68.64
2 10 72.96 80.16 85.92 85.44 80.16 79.2
3 15 82.08 85.92 88.8 88.32 85.92 86.4
4 20 85.92 93.12 93.12 94.08 89.28 90.24
5 30 89.76 95.04 95.04 96.48 91.68 93.12
6 45 94.08 98.88 99.84 99.84 99.36 99.36
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7 60 101.76 102.24 104.64 102.24 103.2 104.64
11.7.2 Results of IN-VITRO release profile of Lamivudine:  
Table.11.7.2.1 In-Vitro Release Profile
Sr.
No.
Time
(min)
F1 F2 F3 F4 F5 F6
1 5 22.35 24.70 28.47 29.64 64.94 65.64
2 10 29.41 31.76 37.17 38.11 74.35 73.41
3 15 38.11 42.58 45.88 46.58 82.11 82.82
4 20 46.58 52.70 55.05 55.52 91.05 90.35
5 30 55.29 63.29 67.29 67.29 96.70 93.17
6 45 64.70 72.47 77.88 79.05 100.70 99.05
7 60 75.52 85.17 87.52 88 103.76 101.4
Table.11.7.2.2 In-Vitro Release Profile
Sr. No. Time(m
in)
F7 F8 F9 F10 F11 F12
1 5 82.823 85.17 89.17 87.29 87.05 86.58
2 10 86.11 89.17 92.23 90.35 91.29 92.70
3 15 92.23 90.35 94.35 94.82 95.29 96
4 20 94.35 95.29 96.23 96.23 97.17 97.41
5 30 96.23 97.88 97.64 99.05 98.823 98.11
6 45 97.88 100.23 100.23 100.23 100.23 100.79
7 60 102.11 103.05 104.23 102.11 102.11 103.29
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Table No: 11.7.3.2 In-Vitro Release Profile of Innovator of Tenofovir DF:
Sr. No. Time(min) %DR
1 5 74.4
2 10 88.32
3 15 90.72
4 20 92.16
5 30 94.08
6 45 100.32
7 60 105.6
Table No: 11.7.3.2 In-Vitro Release Profile of Innovator of Lamivudine:
Sr. No. Time(min) %DR
1 5 88.94
2 10 91.76
3 15 94.58
4 20 96.47
5 30 97.41
6 45 100.23
7 60 103.52
Graphical presentation of Dissolution in0.1N HCl of Tenofovir DF:
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Fig. 11.7.I In-Vitro Release Profile of Viread (Innovator of Tenofovir DF)
Fig.11.7.II In-Vitro Release Profile of F1,F2,F3,F4,F5,F6 with Innovator (Viread)
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Fig.11.7.III In-Vitro Release Profile of  F7,F8,F9,F10,F11,F12 with Innovator (Viread)
Graphical presentation of Dissolution in0.1N HCl of Lamivudine:
Fig. 11.7 IV In-Vitro Release Profile of Epivir (Innovator of Lamivudine)
         
                                                         
DEPT. of Pharmaceutics, R.V.S College of Pharmaceutical Sciences   Page 105
                                                                 Results and discussion
Fig.11.7.V In-Vitro Release Profile of F1,F2,F3,F4,F5,F6 with Innovator(Epivir)
Fig. 11.7.VI I In-Vitro Release Profile of F7,F8,F9,F10,F11,F12 with Innovator
Comparative In-vitro release profile with innovator
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Table no11.7.3.3 Comparative In-vitro release profile with innovator of Tenofovir DF
Sr. No. Time(min) Viread F9
1 5 74.4 72.48
2 10 88.32 85.92
3 15 90.72 88.8
4 20 92.16 93.12
5 30 94.08 95.04
6 45 100.32 99.84
7 60 105.6 104.64
Fig.11.7.VII  In-Vitro Release Profile of F9 with Viread (Innovator)
Table no11.7.3.4.Comparative In-vitro release profile with innovator of Lamivudine
Sr. No. Time(min) Epivir F9
1 5 88.94 87.52
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2 10 91.76 91.29
3 15 94.58 93.88
4 20 96.47 94.823
5 30 97.41 97.88
6 45 100.25 100.23
7 60 103.52 102.11
                  
Fig.11.7.VIII  In Vitro Release Profile of F9 with Epivir (Innovator)
11.8 The results are described as:
Based on the literature review, the immediate release tablet was prepared and the effect of
superdisintegrant and method of formulation on drug release profile was observed.
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The objective of the work was Formulation and evaluation of an immediate release tablets of
the two anti retro-viral drugs 
Formulation F1: 
 In  formulation F1 the two API’s are mixed and done the dry granulation. The
granules then compressed 
 In  formulation  F1  CCS  used  as  disintegrant,  Magnesium  stearate  is  used  as
lubricant, 
 The formulation F1 having concentrations of CCS (7.0%), Magnesium stearate
having concentration (2%)
 The  percentage  drug  release  from  the  tablets  was  found  to  be  slow  when
compared with the innovator sample
 So it was decided to increase concentrations of  CCS
Formulation F2:
  In  this  formulation  F2  also  the  two  API’s  was  mixed  and  done  the  dry
granulation.  But  in  this  the  concentration  of  CCS  was  increased.  Then  these
granules were compressed.
 The formulation F2 having concentration of CCS 14%, Magnesium stearate (2%)
 The formulation resulted in tablets in which the disintegration time was more and
the percentage release was also found to be slow. 
 So it was decided to change the method of formulation by separating the two
API’s and compacted separately and then mixed and compressed.  
Formulation F3:
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  In this formulation F3 the two API’s compacted separately and then mixed and
compressed.
 The formulation F3 having concentration CCS (4.0%) and SSG (5%) per tablet.
 The formulation didn’t  result  in  the improvement  in  dissolution profile  of  the
API’s.
 So it was decided to add extra granular materials after granulation.
Formulation F4:
 In this formulation F4 MCC (Avicel PH 102) and Magnesium Stearate was added
as extragranular materials to the dried granules and mixed.
 In formulation F4 the concentration of CCS and SSG was same as that of F3.
 This  formulation  didn’t  show  improvement  of  %  drug  release  from  the
formulation.
 Hence it was decided to do wet granulation method instead of dry granulation.
Formulation F5:
 In this formulation F5 wet granulation method was used instead of dry granulation
method
 The formulation F5 having concentration CCS (4.0%) and SSG (1.2%)
 This formulation resulted in slightly increased  dissolution than the F4.  The %
release of Lamivudine was found to be satisfactory while % drug release from
Tenofovir DF was very slow.
 So  it  was  decided  to  increase  the  super  disintegrant  concentration  inorder  to
enhance dissolution profile of Tenofovir DF from the formulation.
Formulation F6:
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 In  this  formulation F6 wet  granulation was used and the  concentration  of  the
super  disintegrant  was  increased.  Here  SSG  was  also  added  to  extragranular
portion.
 The formulation F6 having concentration CCS (5%) and SSG (3%).
 The formulation F6 resulted in increase of Lamivudine % release but there is no
improvement in the % release of Tenofovir DF when compared with the innovator
product.
 So it was decided to change the method of formulation by separating the two
API’s and formulate bilayer tablets.
Formulation F7:
 In this formulation F7 the two API’s are granulated by wet granulation method
and the two granules are separated and compressed as bilayer tablets.
 The formulation F7 having concentration CCS (4%) and SSG (3%).
 The formulation F7 resulted in increase of dissolution profile of Lamivudine but
the % release of Tenofovir DF from the formulation was slower than innovator
product.
 So it was decided to increase the concentration of super disintegrants.
Formulation F8:
 In this formulation F8 the concentration of super disintegrants was increased than
F7.
 The formulation F8 having concentration of CCS (6%) and SSG (5%).
 The formulation F8 resulted in increase of dissolution profile of Tenofovir DF
and Lamivudine. The % release of Tenofovir DF and Lamivudine was slightly
faster when compared to F7. But the % release of Tenofovir DF was slower than
innovator product.
 So it was decided to increase the concentration of super disintegrants.
Formulation F9
 In this formulation F9 the concentration of super disintegrants was increased than
F8.
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 The formulation F9 having concentration of CCS (8%) and SSG (7%).
 The formulation F9 resulted in increase of dissolution profile of Tenofovir DF
and Lamivudine and the % release from the formulation was comparable with the
innovator product.
 So it was decided to take a trial to optimize F9 with similar formula as of F9 but
reduce  the  size  of  Tenofovir  DF  by  micronization.  In  order  to  optimize  the
formulation F9.
Formulation F10:
 In this formulation F10 the formula is similar to F9 but in this the trial the size of
Tenofovir DFwas reduced by micronization process ie by passing through 80#. 
 The formulation F10 having concentration of CCS (8%) and SSG (7%).
 The formulation F10 resulted in increase of dissolution profile of Tenofovir DF
and  Lamivudine  and  the  %  release  of  Tenofovir  DF  and  Lamivudine  was
comparable  with  the  innovator  product  but  the  % release  from F9  was  more
comparable with Innovator.
 So it was decided to take a trial  by increasing the concentration of MCC (Avicel
PH 101) and decreasing  the concentration of  Pharmatose 200m
Formulation F11:
 In this formulation F11 the concentration of MCC (Avicel PH 101) is increased
and the concentration of Pharmatose 200m is decreased.
 The formulation F11 having concentration of CCS (8%) and SSG (7%).
 The formulation F11 resulted in decrease of dissolution profile of two API’s when
compared with F9.
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 So it was decided to take a trial by increasing the concentration of CCS and put
the pregelatinized starch in the extra granular part.
Formulation F12:
 In this formulation F12 the concentration of CCS is increased and Pregelatinized
starch was added in extra granular part.
 The formulation F12 having concentration of CCS (9%) and SSG (7%).
 The formulation F12 resulted in decrease of dissolution profile when compared
with F9.
 So it was decided that optimized concentration of CCS is 8% and SSG is 7% and
F9 is the optimized formula.
11.9 DATA ANALYSIS:
Table No: 11.9.1 Determination of order of release of Tenofovir DF & F9
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Time (mins) % Drug
release
SQRT ‘t’ Log ‘t’ % drug
remaining
log % drug
remaining
0 0 0 0 0 0
5 72.48 2.23607 0.699 27.6 1.44
10 85.92 3.16228 1 14.08 1.14
15 88.88 3.87298 1.1761 11.12 1.046
20 93.12 4.47214 1.301 6.88 0.837
30 95.04 5.47723 1.4771 4.96 0.695
45 99.84 6.7082 1.6532 0.16 -0.7959
60 104.6 7.74597 1.7782 -4.65 -
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Fig.11.9.1 First order plot of Tenofovir DF
11.9.2 Drug Release Kinetics of Tenofovir DF, F9
Table No: 11.9.2 Drug Release Kinetics of Tenofovir DF, F9
Batch Zero order First order Higuchi Korsmeyer-
Peppas
R2 K0
(mg/L/
hr)
r2 K1 (h-1) r2 KHg (h-1) r2 N
F9 0.320 0.929 0.925 -0.053 0.603 10.65 0.668 0.989
The curve fitting results of the release rate profile of the designed formulations gave an idea on
the mechanism of drug release.
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 Based on the data analysis the drug release was found to follow First order release kinetics. This
model indicates a coupling of the diffusion and erosion mechanism (Anomalous diffusion) and
indicates that the drug release was controlled by more than one process.
Also, the drug release mechanism was best explained by first order,  as the plots showed the
highest linearity (r2 = 0.925), as the drug release was best fitted in first order kinetics, it indicated
that  the  rate  of  drug  release  takes  place  by  diffusion  and  erosion  mechanism  and  follow
Anomalous diffusion (non-fickian, super case-II transfer).
Table No: 11.9.3 Determination of order of release of Lamivudine & F9
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Time (mins) % Drug
release
SQRT ‘t’ Log ‘t’ % drug
remaining
log % drug
remaining
0 0 0 0 0 0
5 87.5 . . 12.5 1.0969
10 91.28 .	  8.72 0.9405
15 93.88 .		 . 6.12 0.7868
20 94.8 
.

 . 5.2 0.716
30 97.8 .
 .
 2.2 0.3424
45
99.84
.	 .
0.16 -0.7959
60 102.11 .
 .	 -2.11 -
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Fig.11.9.2 First order plot of Lamivudine
11.9.4 Drug Release Kinetics of Lamivudine, F9
Table No: 11.10.2. Drug Release Kinetics of Lamivudine, F9
Batch Zero order First order Higuchi Korsmeyer-
Peppas
R2 K0
(mg/L/
hr)
r2 K1 (h-1) r2 KHg (h-1) r2 N
F9 0.439 1.081 0.925 -0.053 0.730 11.59 0.047 0.279
The curve fitting results of the release rate profile of the designed formulations gave an idea on
the mechanism of drug release.
 Based on the data analysis the drug release was found to follow First order release kinetics. This
model indicates a coupling of the diffusion and erosion mechanism (Anomalous diffusion) and
indicates that the drug release was controlled by more than one process.
Also, the drug release mechanism was best explained by first order,  as the plots showed the
highest linearity (r2 = 0.925), as the drug release was best fitted in first order kinetics, it indicated
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that  the  rate  of  drug  release  takes  place  by  diffusion  and  erosion  mechanism  and  follow
Anomalous diffusion (non-fickian, super case-II transfer).
11.10. Similarity factor f2 and Dissimilarity factor f1
Table no: 11.10.1 Criteria for selection of optimized formulation of Tenofovir DF:
Time (hrs) INNOVATOR
of Tenofovir
DF (R)
F9 (T) /R-T/ /R-T/2 f2 value f1 value
0 0 0 0 0 83.8 1.04
5 74 72 2 4
10 88 86 2 4
15 91 89 2 4
20 92 93 1 1
30 94 95 1 1
45 100 100 0 0
60 106 105 1 1
TOTAL 645 640 11 15
The  dissolution  profiles  of  formulation  F9  and  innovator  product  of  Tenofovir  DF  were
compared by calculating similarity factor (f2) and dissimilarity factor (f1). The f2 and f1 was
found to be 83.08 and 1.04 for the comparison of dissolution profiles of formulation F9 and
innovator product. Hence these two products were considered to be similar.
Hence the above said formulations were selected for further evaluation.
Table no: 11.11.2 Criteria for selection of optimized formulation of Lamivudine:
Time (hrs) INNOVATOR
of
Lamivudine
F9 (T) /R-T/ /R-T/2 f2 value f1 value
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(R)
0 0 0 0 0 87.20 1.04
5 89 88 1 1
10 92 91 1 1
15 95 94 1 1
20 96 95 1 1
30 97 98 1 1
45 100 100 0 0
60 104 102 2 2
TOTAL 673 668 7 9
The dissolution profiles of formulation F9 and innovator product of Lamivudine were compared
by calculating similarity factor (f2) and dissimilarity factor (f1). The f2 and f1 was found to be
87.20  and  1.04  for  the  comparison  of  dissolution  profiles  of  formulation  F9  and  innovator
product.  Hence  these  two  products  were  considered  to  be  similar.  Hence  the  above  said
formulations were selected for further evaluation
11.12. STABILITY STUDY OF IMMMEDIATE RELEASE BI-LAYER TABLET
Stability data of Film Coated Immediate Release Bilayer Tablet of Tenofovir DF and 
Lamivudine of formulation F9 are given below
Table no.11.12.1 Stability study of Bi-layer coated tablet of F9
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                                                                 Results and discussion
Test Specification Initial One month
Description
White colored,
capsule shape
biconvex film coated
bilayered tablet with
embossing “I” on
one side and “49” on
other side.
White colored,
capsule shape
biconvex film coated
bilayered tablet with
embossing “I” on
one side and “49” on
other side.
White colored,
capsule shape
biconvex film coated
bilayered tablet with
embossing “I” on one
side and “49” on
other side.
Dissolution:
Medium=900ml
0.1N HCl, USP
Apparatus II, 50
RPM, for 60min.
For Tenofovir DF
In 60 min
= 104.86%
In 60 min
= 102.96%
Dissolution:
Medium=900ml,
0.1 N HCl, USP
Apparatus I, 50
RPM, for 60min.
For Lamivudine
In 60 min
= 102.86%
In 60 min
= 101.74%
Assay
90 % to 110 % of
stated amount of
Tenofovir DF
Mean = 98.22%
Mean = 97.22%
90 % to 110 % of
stated amount of
Lamivudine
Mean = 99.21% Mean = 98.05%
Thickness --- 7.40-7.50mm 7.40-7.50mm
Hardness --- 22-26kp 23-26kp
Disintegration Time --- 1-3min 1-3 min
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 Summary
   12. SUMMARY
      Tenofovir DF and Lamivudine are nucleotide and nucleoside analog reverse transcriptase
inhibitors and they are used in the treatment of AIDS & Hepatitis. The half-life of Tenofovir DF
was 17 hours and Lamivudine was 7 hours. The daily dose of the two API’s is 300 mg per day. So
it was not that much required to formulate them in to sustained release formulation.The innovator
samples  of  the  two  API’s  were  in  immediate  release  formulation.So  it  was  formulated  as
immediate release formulation.  But  when the API’s  are  formulated  as  combination tablets  the
percentage release was found to be very less. So it was formulated as bilayered tablets.
     The daily dose of Tenofovir DF & Lamivudine was described as 300mg/300mg for only once
daily.
     Therefore  an  attempt  is  made  to  formulate  immediate  release  formulation,  which  has
disintegration time less than 15 min and the dissolution profile of the drug with very faster release.
      In the formulation of immediate release tablet Croscarmellose sodium and Sodium starch
glycolate  –Type A was used as  superdisintegrants,  Pregelatinized starch used as binder.  Other
excipients  used  are  lactose  monohydrate  (diluents)  Microcrystalline  Cellulose  (diluents),
Magnesium stearate  (lubricating agent).  Fourier  transform Infrared  spectroscopy confirmed the
absence of any drug/polymers/excipients interactions.
The formulations F1, F2, F3 and F4 were prepared by dry granulation method, formulation F5
and F6 were prepared by wet granulation method and formulation F7 to F12 were formulated as
bilayer tablets and the granules were prepared by wet granulation method.
Super  disintegrants  croscarmellose  sodium and  sodium starch  glycolate  were  used  to  give
immediate release for the tablets.
The tablets were compressed using 19.8× 10.2 mm Capsule shaped punch with embossing “I”
on one side and “49” on other side and compressed on KAMBERT 8 station rotary compression
machine and KARNAVATI 8 station rotatory bilayer machine.
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 Summary
     The  prepared  immediate  release  tablets  were  evaluated  for  hardness,  weight  variation,
thickness, friability, drug content uniformity, in-vitro dissolution studies. F9 formulation showed
good evaluation studies and an immediate drug release. 
Finally, Innovator obtained from the market and the dissolution profile of the final batch was
matched with the innovator’s dissolution profile.
From the dissolution profile, f1 & f2 value was calculated and from that value optimize batch of
Tenofovir DF and Lamivudine was selected. 
All formulations were subjected for four different models viz. Zero order, First order, Higuchi
and Peppas model equations and the formulation best fit in to the First-order release kinetics that
indicate the formulation had released the drug by concentration gradient. It was revealed that super
disintegrants and method of formulation had significant influence on drug release. 
Final Batch was charged for the stability study with packing at 400 C/75% RH   for 1 month.
The results obtained after the stability period was not having any change than the initial results.
Thus conclusion can be made that stable dosage form can be developed for Tenofovir DF &
Lamivudine by bilayer method for immediate release by wet granulation.
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 Conclusion
13. CONCLUSION
      The aim of the present study was to formulate and evaluate a stable immediate release tablet of
Tenofovir DF and Lamivudine to maintain constant therapeutic levels of the drug and compare
with  the  innovator  samples. The  immediate  release  bilayer  tablets  were  prepared  by  wet
granulation method with different concentrations of CCS & SSG Type-A as superdisintegrants.  
 The formulations F1, F2, F3 and F4 were prepared by dry granulation method. And the drug
release of above formulations was slow. In all these formulations only 80% of the drug release was
found within 60min for Tenofovir DF and only 90% drug release for Lamivudine within 60 min.
The formulation F5 and F6 were prepared by wet granulation method which resulted in increase in
dissolution rate of Tenofovir DF and Lamivudine but it was not matching with innovator % drug
release.
The formulation F7 to F12 were formulated as bilayer tablets and the granules were prepared by
wet granulation method.
In the formulation F7 the concentration of superdisintegrants CCS was 4% and SSG was 3%. Here
the drug release for Lamivudine was satisfactory but for Tenofovir DF it was slow.
In the formulation F8 the concentration of super disintegrants CCS was 6% and SSG was 5%. Here
also drug release for Lamivudine was satisfactory but for Tenofovir DF it was slow.
In the formulation F9 the concentration of super disintegrants was CCS 8% and SSG was 7%. Here
drug release of both Tenofovir DF and Lamivudine was comparable with innovator on the basis of
similarity and dissimilarity factors.
The formulations F10,  F11 and F12 were done to optimize the F9.In  the formulation F10 the
concentration of super disintegrants was CCS 8% and SSG 7%. Here the Tenofovir DF drug was
micronized to reduce the particle size. Then the drug release of both Tenofovir DF and Lamivudine
was comparable with innovators but F9 was more comparable with innovator.
In  F11  the  concentration  of  Lactose  monohydrate  (pharmatose  200m)  and  microcrystalline
cellulose (Avicel PH 101) was changed. In F12 the concentration of CCS increased and binder
Pregelatinized starch added as extragranular part of Tenofovir DF.
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 Conclusion
 The results of dissolution studies indicated that formulation F9 is the most successful of the study,
exhibited drug release pattern close to innovator drug release profile. The drug content of F9 was
found to be better than other formulation, so that it was selected as optimized formulation. The
designed immediate release bilayered tablets of formulation F9 release 85.92% of Tenofovir DF in
10 min and 104.65% at 60min and 91.29% of Lamivudine in 10 min and 102.11% at  60min.
Regulated drug release in First order kinetics attained with this formulation, as the highest linearity
(r2 = 0.925) showed with first order plot.
             The developed immediate release bilayer tablet formulation was quite stable with regard to
drug content, physical properties and dissolution rate. 
Hence it can be concluded that once daily immediate release bilayer tablet of Tenofovir DF and
Lamivudine having satisfactory drug release profile which may provide an increased therapeutic
efficacy. 
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